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Nucleoporin fragments. Domain boundaries of all nucleoporin fragments used throughout the text are 





Reconstitution of the CNC. SEC and SDS-PAGE analysis for the reconstitution of (A) the 
Nup120•Nup37•ELYS•Nup85 hetero-tetramer, (B) the CNC-hexamer, and (C) the CNC-octamer. SEC 
profiles of nucleoporins or nucleoporin complexes are shown individually (blue and red) and after their 
preincubation (green). All SEC profiles were obtained using a Superdex 10/300 GL column. Gray bars 
indicate fractions that were resolved on SDS-PAGE gels and visualized by Coomassie staining. The 




Reconstitution of the IRC•Nup53 complex. SEC-MALS and SDS-PAGE analysis of (A) the 
reconstitution of the IRC•Nup53 hetero-heptamer and (B) the interaction of IRC•Nup53 with Nup188. 
SEC-MALS profiles of nucleoporins or nucleoporin complexes are shown individually (blue and red) 
and after their preincubation (green). All SEC profiles were obtained using a Superose 6 10/300 GL 
column. Measured molecular masses are indicated for the peak fractions. Gray bars indicate fractions 
that were resolved on SDS-PAGE gels and visualized by Coomassie staining or by immunoblotting with 
a mouse anti-AviTag antibody. As Nup188 and Nup192 cannot be distinguished by SDS-PAGE 
analysis, lack of Nup192 displacement from the IRC by Nup188 was confirmed by western blotting 





Reconstitution of NPC core protomers. (A-D) SEC-MALS and SDS-PAGE analysis corresponding to 
Fig. 1, D to G. SEC-MALS profiles of nucleoporin complexes are shown individually (blue and red) and 
after their preincubation (green). All SEC profiles were obtained using a Superose 6 10/300 GL column. 
Measured molecular masses are indicated for the peak fractions. Gray bars indicate fractions that were 




The CNC-hexamer interacts with Nup145NAPD. SEC-MALS and SDS-PAGE analysis of the CNC-
hexamer interaction with (A) Nup145N, (B) Nup145NAPD, and (C) Nup145N PreS preincubated with 
PreScission protease. SEC-MALS profiles of nucleoporins or nucleoporin complexes are shown 
individually (blue and red) and after their preincubation (green). All SEC profiles were obtained using a 
Superose 6 10/300 GL column. Measured molecular masses are indicated for the peak fractions. Gray 
bars indicate fractions that were resolved on SDS-PAGE gels and visualized by Coomassie staining. As 
reference, the domain structure of Nup145N PreS is shown, indicating the construct boundaries and 
PreScission cleavage site with a black bar and a black triangle, respectively. After cleavage with 
PreScission protease, Nup145NAPD co-elutes with the CNC-hexamer, whereas Nup145NMID does not 





Incorporation of Nup145N into complexes with CNC-hexamer or Nup188•Nic96•Nup53•CNT is 
exclusive of Nup145N binding to Nup82NTD•Nup159T. SEC-MALS and SDS-PAGE analysis of the 
CFC interaction with (A) the CNC-hexamer or (B) the Nup188•Nic96•Nup53•CNT complex. SEC-MALS 
profiles of nucleoporin complexes are shown individually (blue and red) and after their preincubation 
(green). SEC profiles were obtained using a Superose 6 10/300 GL column. Measured molecular 
masses are indicated for the peak fractions. Gray bars indicate fractions that were resolved on SDS-
PAGE gels and visualized by Coomassie staining. In both preincubations, Nup145N incorporates 
stoichiometrically into the complexes, but the Nup82NTD•Nup159T hetero-dimer does not. However, 




Scaffold nucleoporins are assembled by the linker nucleoporins. SEC-MALS and SDS-PAGE 
analysis corresponding to Fig. 2, A to C. (A) For interaction analysis between scaffold nucleoporins, 
SEC-MALS profiles of nucleoporins are shown individually (blue, purple, orange, or green) and after 
their preincubation (black). (B) To analyze the assembly of Nup192, Nup170, and Nic96SOL with the 
linker nucleoporins Nup53 and Nup145N, SEC-MALS profiles of the scaffold mixture (blue), the linker 
mixture (red), or after their preincubation (black) are shown. (C) To analyze the assembly of Nup188, 
Nup170 and Nic96SOL with the linker nucleoporins Nup53 and Nup145N, SEC-MALS profiles of the 
scaffold mixture (purple), the linker mixture (red), or after their preincubation (black) are shown. All SEC 
profiles were obtained using a Superose 6 10/300 GL column. Measured molecular masses are 
indicated for the peak fractions. Gray bars indicate fractions that were resolved on SDS-PAGE gels and 
visualized by Coomassie staining. Because Nup188 could not be incorporated into the IRC, Nup188 




Identification of interactions between Nup53 and the scaffold nucleoporins. (A-E) SEC-MALS and 
SDS-PAGE analysis for Fig. 2D. SEC-MALS profiles of nucleoporins are shown individually (blue and 
red) and after their preincubation (green). All SEC profiles were obtained using a Superdex 200 10/300 
GL column. Measured molecular masses are indicated for the peak fractions. Gray bars indicate 
fractions that were resolved on SDS-PAGE gels and visualized by Coomassie staining. Robust 
complex formation with Nup53 was observed for Nic96SOL, Nup170, and Nup192. Interactions of Nup53 




Identification of interactions between Nup145N and scaffold nucleoporins. (A-C) SEC-MALS and 
SDS-PAGE analysis for Fig. 2E. SEC-MALS profiles of nucleoporins are shown individually (blue and 
red) and after their preincubation (green). All SEC profiles were obtained using a Superdex 200 10/300 
GL column. Measured molecular masses are indicated for the peak fractions. Gray bars indicate 
fractions that were resolved on SDS-PAGE gels and visualized by Coomassie staining. Robust 
complex formation with Nup145N was observed for Nup170, Nup188, and Nup192. We previously 




Identification of hetero-trimeric complexes assembled by Nup53. (A-E) SEC-MALS and SDS-
PAGE analysis corresponding to Fig. 2D. Purified hetero-dimeric Nup53 complexes were tested for 
their ability to form hetero-trimers with an additional scaffold nucleoporin. SEC-MALS profiles of 
nucleoporins or nucleoporin complexes are shown individually (blue and red) and after their 
preincubation (green). All SEC profiles were obtained using a Superose 6 10/300 GL column. 
Measured molecular masses are indicated for the peak fractions. Gray bars indicate fractions that were 
resolved on SDS-PAGE gels and visualized by Coomassie staining. Nup53 is able to bind 
simultaneously to Nup170, Nic96SOL, and Nup192. The interaction of the Nup170•Nup53 hetero-dimer 





Identification of hetero-trimeric complexes assembled by Nup145N. (A-G) SEC-MALS and SDS-
PAGE analysis corresponding to Fig. 2E. Purified hetero-dimeric Nup145N complexes were tested for 
their ability to form hetero-trimers with an additional scaffold nucleoporin. SEC-MALS profiles of 
nucleoporins or nucleoporin complexes are shown individually (blue, red, and purple) and after their 
preincubation (green). SEC profiles were obtained using either a Superose 6 10/300 GL column or a 
Superdex 200 10/300 GL column as indicated. Measured molecular masses are indicated for the peak 
fractions. Gray bars indicate fractions that were resolved on SDS-PAGE gels and visualized by 
Coomassie staining or by western blot analysis with a mouse anti-AviTag antibody. Hetero-trimeric 
complex formation was determined on the basis of a shift in elution volume, an increase in measured 
molecular mass, and the presence of all three proteins in the higher molecular mass fractions. For 
preincubations with Nup188 or Nup188•Nup145N, only minor shifts in elution volume and no increases 
in the measured molecular masses were observed, indicating the formation of a mixture of species 
rather than stable hetero-trimeric complexes as seen between Nup170, Nup192, and Nup145N. As 
Nup188 and Nup192 cannot be distinguished by SDS-PAGE, western blot analysis was employed to 




Binding sites for linker nucleoporins on Nup170 and Nup192 are distinct and compatible. (A-C) 
SEC-MALS profiles of nucleoporins or nucleoporin complexes are shown individually (blue, red, or 
yellow) and after their preincubation (green). SEC profiles were obtained using a Superdex 200 10/300 
GL column for panels (A, B) and a Superose 6 10/300 GL column for panel (C). Measured molecular 
masses are indicated for the peak fractions. Gray bars indicate fractions that were resolved on SDS-
PAGE gels and visualized by Coomassie staining. We were unable to obtain an accurate molecular 
mass measurement for the preincubation of Nup53 with Nup170•Nup145N, as indicated by an asterisk 




Nup192 recognizes Nup5331-67. SEC-MALS and SDS-PAGE analysis corresponding to Fig. 2F. SEC-
MALS profiles of nucleoporins are shown individually (blue and red) and after their preincubation 
(green). All SEC profiles were obtained using a Superdex 200 10/300 GL column. Measured molecular 
masses are indicated for the peak fractions. Gray bars indicate fractions that were resolved on SDS-




Nic96SOL recognizes Nup5369-90 and Nup531-90 binds simultaneously to Nup192 and Nic96SOL. (A-
C) SEC-MALS and SDS-PAGE analysis corresponding to Fig. 2F. SEC-MALS profiles of nucleoporins 
or nucleoporin complexes are shown individually (blue and red) and after their preincubation (green). 
All SEC profiles were obtained using a Superdex 200 10/300 GL column. Measured molecular masses 
are indicated for the peak fractions. Gray bars indicate fractions that were resolved on SDS-PAGE gels 
and visualized by Coomassie staining. The Nup53 binding sites for Nic96SOL and Nup192 map to 




Nup170NTD recognizes Nup53329-361. (A, B) SEC and SDS-PAGE analysis corresponding to Fig. 2F. 
SEC profiles of nucleoporins are shown individually (blue and red) and after their preincubation (green). 
All SEC profiles were obtained using a Superdex 200 10/300 GL column. Gray bars indicate fractions 




Nup170CTD recognizes Nup145N729-750. (A, B) SEC and SDS-PAGE analysis corresponding to Fig. 2F. 
SEC profiles of nucleoporins are shown individually (blue and red) and after their preincubation (green). 
All SEC profiles were obtained using a Superdex 200 10/300 GL column. Gray bars indicate fractions 





Nup192 recognizes Nup145N606-683 primarily with its NTD. (A-E) SEC-MALS and SDS-PAGE 
analysis corresponding to Fig. 2F. SEC-MALS profiles of nucleoporins are shown individually (blue and 
red) and after their preincubation (green). All SEC profiles were obtained using a Superdex 200 10/300 
GL column. Measured molecular masses are indicated for the peak fractions. Gray bars indicate 
fractions that were resolved on SDS-PAGE gels and visualized by Coomassie staining. Nup192 binds 
to a minimal sequence on Nup145N between residues 606-683. After cleavage of Nup145NPreS with 
PreScission protease, Nup145NMID co-elutes with Nup192, whereas Nup145NAPD does not interact with 
Nup192. As a reference, the domain structure of Nup145NPreS is shown, indicating the construct 
boundaries and PreScission cleavage site with a black bar and a black triangle, respectively. Nup145N 
forms a stoichiometric complex with Nup192NTD, but Nup145N binding to Nup192CTD and Nup192TAIL 






Mapped minimal linker nucleoporin fragments are specific for the identified binding partners. 
(A-H) SEC-MALS profiles of nucleoporins are shown individually (blue and red) and after their 
preincubation (green). All SEC profiles were obtained using a Superdex 200 10/300 GL column. 
Measured molecular masses are indicated for the peak fractions. Gray bars indicate fractions that were 
resolved on SDS-PAGE gels and visualized by Coomassie staining. The minimal sequence fragments 
of the linker nucleoporins Nup53 and Nup145N did not interact with other scaffold nucleoporins, 





Nup188 recognizes Nup145N606-750 primarily via its NTD. (A-E) SEC-MALS and SDS-PAGE analysis 
corresponding to Fig. 2F. SEC-MALS profiles of nucleoporins are shown individually (blue and red) and 
after their preincubation (green). All SEC profiles were obtained using a Superdex 200 10/300 GL 
column. Measured molecular masses are indicated for the peak fractions. Gray bars indicate fractions 
that were resolved on SDS-PAGE gels and visualized by Coomassie staining. Nup188NTD is 
responsible for binding Nup145N. After Nup145NPreS cleavage with PreScission protease, Nup145NMID 
co-elutes with Nup188, whereas Nup145NAPD does not interact with Nup188. As reference, the domain 
structure of Nup145NPreS is shown, indicating the construct boundaries and PreScission cleavage site 
with a black bar and a black triangle, respectively. Nup188 binds to a minimal sequence on Nup145N 
between residues 606-750, but does not interact with the minimal Nup145N binding sequences for 




Nup192TAIL and Nup188TAIL bind to partially overlapping sites in Nic96R2. (A) Domain boundaries of 
Nic96 with the protein sequence corresponding to the R2 region shown below. Black lines indicate 
construct boundaries for Nic96R2, Nic96R2∆2, and Nic96R2∆4. The effects of Nic96R2 alanine mutations on 
Nup192TAIL and Nup188TAIL binding are indicated by colored dots; no effect (green), reduced binding 
(orange), and complete disruption (red). (B-D) SEC and SDS-PAGE analysis corresponding to Fig. 2F. 
SEC profiles of nucleoporins are shown individually (blue and red) and after their preincubation (green). 
Nic96R2∆2 is insoluble when expressed alone and therefore was expressed and purified in the presence 
of Nup188TAIL. (E, F) Mutational analysis of the Nic96R2 interaction with Nup192TAIL and Nup188TAIL. 
SEC profiles of Nup192TAIL or Nup188TAIL are shown individually (gray) and after preincubation with wild 
type Nic96R2 (black) and are annotated with arrows of the same color. SEC profiles of mutant proteins 
preincubated with Nic96R2 are colored according to measured effect as in panel (A). All SEC profiles 
were obtained using a Superdex 200 10/300 GL column. Gray bars indicate fractions that were 
resolved on SDS-PAGE gels and visualized by Coomassie staining. (G) Table summarizing the 
measured effects of Nic96R2 mutation on Nup192TAIL and Nup188TAIL binding colored according to panel 
(A): no effect (+++), moderate effect (+), abolished binding (-). The Nic96R2 F275A mutant abolished 










Multispecies sequence alignment of Nup170. Sequences from twelve diverse species were aligned 
and colored by sequence similarity according to the BLOSUM62 matrix from white (less than 55 % 
similarity), to yellow (55 % similarity), to red (100 % identity). Numbering below alignment is relative to 
the C. thermophilum sequence. Secondary structure observed in the Nup170 structures is shown above 
the alignment: α-helices (red bars), β-sheets (blue bars), and unstructured regions (black lines). 
Mutations that affect Nup53 or Nup145N binding identified by a mutational analysis (Fig. 3; 
figs. S22; fig. S23) are indicated by circles above the alignment and colored according to the measured 
effect; weak effect (yellow), moderate effect (orange), abolished binding (red). Dashed lines indicate 




Mutational analysis of Nup170NTD•Nup53 and proposed interactions with the nuclear envelope. 
SEC interaction experiments performed with mutants of (A) Nup170NTD and (B) GST-Nup53329-361. SEC 
profiles of wild type Nup170NTD (dark gray) and GST-Nup53329-361 (light gray) are shown individually and 
after preincubation (black) and are annotated with arrows of the same color. Mutant SEC profiles are 
colored according to the measured effect: no effect (green), weak effect (yellow), moderate effect 
(orange), and abolished binding (red). All SEC profiles were obtained using a Superdex 200 10/300 GL 
column. (C) Nup170NTD is shown in cartoon representation and possible membrane interaction motifs 
are highlighted. The Nup170 β-propeller domain contains two sequence motifs, WF and ALPS, which 
are located on the same face directly adjacent to a C-terminal amphipathic helix of Nup53 that has 
previously been shown to anchor Nup53 to the nuclear envelope (18, 19). (D) Helical wheel diagrams 
of the Nup170 ALPS motif in C. thermophilum, S. cerevisiae, and H. sapiens are shown with 
hydrophobic and polar residues colored in yellow and purple, respectively. The universally conserved 
proline residue on the polar face of the helix, a feature reminiscent of antimicrobial membrane-




Mutational and structural analyses of the Nup170CTD-Nup145N interaction. SEC interaction 
experiments performed with mutants of (A) Nup170CTD and (B) GST-Nup145N729-750. SEC profiles of 
wild type Nup170CTD (dark gray) and GST-Nup145N729-750 (light gray) are shown individually and after 
preincubation (black) and are annotated with arrows of the same color. Mutant SEC profiles colored 
according to measured effect: no effect (green), weak effect (yellow), moderate effect (orange), and 
abolished binding (red). All SEC profiles were obtained using a Superdex 200 10/300 GL column. (C) 
Comparison of the Nup145N binding pocket in Nup170 in the bound and apo states reveals minimal 




The Nup170CTD-Nup145N interaction is conserved in humans and partially disrupted by 
phosphomimetic mutations. (A) Sequence alignment of Nup145N729-750 and hsNup98596-617. 
Nup145N729-750 mutants are indicated by circles and colored as in Fig. 3J. hsNup98 residues S608 and 
S612 that are phosphorylated during mitosis are indicated (35). (B) Close-up view of the Nup170CTD-
Nup145N interaction indicating the positioning of T741 and S745 in Nup145N, which correspond to the 
mitotically phosphorylated hsNup98 residues S608 and S612. (C) SEC interaction analysis of the 
hsNup155CTD-hsNup98596-617 interaction. SEC profiles of hsNup155CTD (light gray) and hsNup98596-617 
(dark grey), the preincubation of the wild type proteins (black), and the preincubation of hsNup155CTD 
with the phosphomimetic hsNup98596-617 S608E/S612E double mutant (red) are shown. All SEC profiles 
were obtained using a Superdex 200 10/300 GL column. Gray bars indicate fractions that were 




Superposition-generated structures of full-length Nup170. (A) The construct boundaries of 
Nup170SOL are indicated by a black line above the domain structure. The crystal structures of 
Nup170SOL (green), Nup170NTD (light orange), and Nup170CTD (dark orange), and their superposition are 
shown in cartoon representation. See also Movie 1. (B) Complete conformational range of Nup170 
generated by superposing different conformations of Nup170CTD with the structure of Nup170SOL. 
Conformations were obtained from the Nup170SOL structure (conformation 1), different molecules in the 
asymmetric unit of the apo Nup170CTD structures (conformations 2, 3, and 4), and different molecules in 
the asymmetric unit of the Nup170CTD•Nup145N complex structure (conformations 5, 6, 7, and 8). The 






Surface properties of Nup170. Surface representations of Nup170 is shown in four different 
orientations related by 90° rotations. Nup53 and Nup145N binding interfaces are outlined in black. (A) 
Surface representation with the Nup53 and Nup145N binding sites colored in purple and cyan, 
respectively. (B) Surface representation colored according to sequence identity based on the alignment 
in fig. S21. (C) Surface representation colored according to electrostatic potential from -10 kBT/e (red) 








Multispecies sequence alignment of Nic96SOL. Sequences from twelve diverse species were aligned 
and colored by sequence similarity according to the BLOSUM62 matrix from white (less than 
55 % similarity), to yellow (55 % similarity), to red (100 % identity). Numbering below alignment is 
relative to the C. thermophilum sequence. Secondary structure observed in the Nic96 structure is 
shown above the alignment: α-helices (red bars), β-sheets (blue bars), and unstructured regions (black 
lines). The secondary structure of R2 is unknown, but predicted to be helical, which is indicated by a 
red outline. Mutations that affect binding to Nup53, Nup188, or Nup192 found by mutational analysis 
(figs. S20 and S28) are indicated by circles above the alignment and colored according to the 
measured effect; weak effect (yellow), moderate effect (orange), and abolished binding (red). 




Identification of Nic96SOL mutants that disrupt Nup53 binding. (A) SEC interaction analysis 
between Nic96SOL mutants and SUMO-Nup53R2. SEC profiles are colored according to the effect on 
SUMO-Nup53R2 binding; no effect (green), moderate effect (orange), or abolished binding (red). For 
reference, the SEC profile of the wild type Nic96SOL•SUMO-Nup53R2 hetero-dimer (black) is shown. All 
SEC profiles were obtained using a Superdex 200 10/300 GL column. A gray bar indicates fractions 
that were resolved on SDS-PAGE gels and visualized by Coomassie staining. (B) The structure of 
Nic96SOL•Nup53R2 is shown in cartoon representation. The inset illustrates the region that is expanded 




Surface properties of Nic96SOL. Surface representations of Nic96SOL are shown in four different 
orientations related by 90° rotations. The Nup53 binding interface is outlined in black. (A) Surface 
representation with the Nup53 binding site colored in purple. (B) Surface representation colored 
according to sequence identity based on the alignment in fig. S27. (C) Surface representation colored 













Multispecies sequence alignment of Nup192. Sequences from twelve diverse species were aligned 
and colored by sequence similarity according to the BLOSUM62 matrix from white (less than 55 % 
similarity), to yellow (55 % similarity), to red (100 % identity). Numbering below alignment is relative to 
the C. thermophilum sequence. Secondary structure observed in the Nup192 structure is shown above 
the alignment: α-helices (red bars), β-sheets (blue bars), and unstructured regions (black lines). A 





Superposition-generated structure of full-length Nup192. Cartoon representations of the crystal 
structures of Nup192∆HEAD (colored as in Fig. 4F), Nup192NTD (yellow), and Nup192TAIL (red) and their 
superposition are shown. A cartoon representation of the superposition-generated structure of full-




Surface properties of Nup192. Surface representations of Nup192 are shown in four different 
orientations. The surfaces corresponding to previously identified point mutations that disrupt 
interactions with Nup53 or Nic96 are outlined in black. (A) A surface representation of Nup192 with 
previously identified point mutations that disrupt interactions with Nup53 or Nic96 colored purple or 
green, respectively (15, 20). (B) Surface representation colored according to sequence identity based 
on the alignment in fig. S30. (C) Surface representation colored according to electrostatic potential from 




Domain structures of symmetric core nucleoporins are conserved between H. sapiens and C. 
thermophilum. Predicted domain boundaries are shown for the symmetric core nucleoporins from H. 






Flowchart of the incremental approach used to dock crystal structures into the cryoET 
reconstruction of the intact human NPC. For each docking step, the crystal structures used for 
global searches are shown on the left (search model) and the cryoET reconstruction the searches were 
performed with is shown in the middle (search region). Newly assigned density that was removed from 
the cryoET reconstruction in subsequent searches is shown on the right and colored as the crystal 
structure that was placed (assigned density). The remaining unassigned density and combined 




Docking of the CNC-hexamer and Nup84•Nup133 crystal structures into the cryoET 
reconstruction of the intact human NPC. On the left, histograms of the cross-correlation scores from 
a global search with 50,000 random initial placements are shown for (A) the yeast CNC-hexamer (PDB 
ID 4XMM) and (B) hsNup84•hsNup133 hetero-dimer (PDB ID 3I4R) (14, 23). Arrows and 
corresponding numbers indicate the unique solutions that were accepted and the rank of the score, 
respectively. The arrangement of the unique solutions in one spoke is shown in the middle. The 
densities corresponding to the nuclear envelope and the NPC are colored in dark gray and white, 
respectively. Representative views illustrating the quality of the fits are shown on the right. The 
numbers on the top left of the box indicate which solution is depicted. (C) Manual docking of Nup43 
(PDB ID 4I79; periwinkle), Nup37 (PDB ID 4FHM; pink), and Nup133NTD (PDB ID 1XKS; turquoise) β-





Docking of the superposition-generated full-length Nup170 and Nup192 structures into the 
cryoET reconstruction of the intact human NPC. On the left, histograms of the cross-correlation 
scores from a global search with 50,000 random initial placements are shown for (A) Nup170 
conformation I (light orange), (B) Nup170 conformation II (dark orange), and (C) Nup192 (blue), 
Nup188 (purple). The Nup170 conformations I and II correspond to conformations 5 and 2, 
respectively, in fig. S25. Arrows and corresponding numbers indicate the unique solutions that were 
accepted and the rank of the score, respectively. For Nup192, we accepted 5 placements from the 
global search results, two placements in the inner ring, two placements in the outer rings, and one 
placement on the nuclear peripheral side of the inner ring. A matching cytoplasmic peripheral 
placement was not found in global searches, but the manual placement on the cytoplasmic peripheral 
side of the inner ring generated a score which would rank as the 9th highest score (asterisk). The 
arrangement of the unique solutions in one spoke is shown in the middle. The densities corresponding 
to the nuclear envelope and the NPC are colored in dark gray and white, respectively. Representative 
views illustrating the quality of the fits are shown on the right. The numbers on the top left of the box 




Docking of Nic96SOL and CNT crystal structures into the cryoET reconstruction of the intact 
human NPC. On the left, histograms of the cross-correlation scores from a global search with 50,000 
random initial placements are shown for (A) Nic96SOL•Nup53R2 (green) and (B) CNT•Nic96R1 (PDB 
5CWS; red). Arrows and corresponding numbers indicate the unique solutions that were accepted and 
the rank of the score, respectively. The arrangement of the unique solutions in one spoke is shown in 
the middle. The densities corresponding to the nuclear envelope and the NPC are colored in dark gray 
and white, respectively. Representative views illustrating the quality of the fits are shown on the right. 
The numbers on the top left of the box indicate which solution is depicted. (C) Crystal structures of the 
C. thermophilum CNT•Nic96R1 hetero-tetramer (PDB ID 5CWS; red and green; top), the X. laevis CNT 
hetero-trimer (PDB ID 5C3L; light cyan; middle) and ferredoxin-like domain (PDB ID 5C2U; purple; 
middle), and their superposition (bottom) are shown in cartoon representation (15, 16). (D) The four 
knobs of unexplained density directly adjacent to the docked CNT•Nic96R1 crystal structures (colored in 
cyan and marked with arrows) are readily explained by the presence of the ferredoxin-like domain, a 
metazoan-specific insertion in Nup57. Side views from within the central transport channel of the NPC 
(top) and top views from the cytoplasm (bottom) are shown of the cryoET reconstruction with the 
docked CNT•Nic96R1 crystal structures (left), the model of X. laevis CNT with ferredoxin-like domain 




Crystal structures of Nup53RRM and Nup145NAPD•Nup145CN. (A) Crystal structures of C. 
thermophilum Nup53RRM (purple), H. Sapiens Nup53RRM (PDB ID 4LIR; gray), and their superposition 
are shown in cartoon representation. The core fold is conserved, but there are minor alterations in the 
size of helices and loops. (B) Crystal structures of the C. thermophilum Nup145NAPD•Nup145CN 
complex (cyan), the H. sapiens Nup98APD•Nup96N complex (PDB ID 1KO6; light gray), and their 
superposition are shown in cartoon representation. As previously observed for the 
hsNup98APD•hsNup96N hetero-dimer, fusion of the Nup145CN peptide to Nup145NAPD and introduction 
of the catalytically inactive T994A mutation allowed for structure determination of the 
Nup145NAPD•Nup145CN complex. Nup145CN occupied the same binding grove as previously observed 
in the hsNup98•hsNup96 complex (30). As references, the domain structures of Nup53, Nup145N, and 





Nup53RRM does not interact with inner ring scaffold nucleoporins or the CNC-hexamer. (A-E) 
SEC-MALS profiles of nucleoporins or nucleoporin complexes are shown individually (blue and red) 
and after their preincubation (green). SEC profiles were obtained using a Superdex 200 10/300 column 
or Superose 6 10/300 column as indicated. Measured molecular masses are indicated for the peak 





Identification of a third pair of Nup170 molecules in the inner ring of the cryoET reconstruction 
of the intact human NPC. (A) Views of the cryoET density in the inner ring illustrating all density and 
the docked proteins from the unbiased search (far left), the cryoET density remaining after removal of 
the assigned density and the docked proteins (middle left), the remaining cryoET density without the 
docked proteins from the unbiased search revealing density that is shaped like a Nup170 molecule 
colored in orange (middle right), and the same density with a third conformation of Nup170 docked (far 
right). (B) Search results for two additional Nup170 molecules fitted into a cryoET map from which the 
density for the CNCs had been removed. The histogram on the left shows the cross-correlation scores 
for a pair of Nup170 conformation III (light orange) from a global search with 50,000 random initial 
placements. Nup170 conformation III corresponds to conformation 8 in fig. S25. Arrows and 
corresponding numbers indicate the unique solutions that were accepted and the rank of the score, 
respectively. The arrangement of the unique solutions in one spoke is shown in the middle. The 
densities corresponding to the nuclear envelope and the NPC are colored in dark gray and white, 
respectively. Representative views illustrating the quality of the fits are shown on the right. The 
numbers on the top left of the box indicate which solution is depicted. (C) A histogram illustrating the 
search results for fitting Nup170 conformation III into a cryoET map of the inner ring from which the 




Summary of crystal structure docking into the cryoET reconstruction of the intact human NPC. 
(A) Crystal structures of the symmetric core nucleoporins that could be successfully docked into a 
cryoET reconstruction of the intact human NPC. (B-D) Crystal structures of symmetric core nucleoporin 
domains, the cytoplasmic filament nucleoporins, and nuclear basket nucleoporins, which were not 
docked due to their small size, indistinctive shape, or lack of biochemical restraints. Cytoplasmic and 
nuclear views of the cryoET reconstruction of the intact human NPC are shown on the right. The 
assigned density of the symmetric NPC core is colored in gray and the unassigned densities on the 
cytoplasmic and nuclear faces are colored in cyan and purple, respectively. The volume of the 
unassigned density appears to be sufficient to accommodate the majority of the remaining structured 
protein mass of the asymmetric cytoplasmic filament and nuclear basket nucleoporins. All crystal 




Comparison of the distal and proximal CNC docking solutions. Individual distal (multicolored; left) 
and proximal (gray; middle) CNCs are shown in cartoon representation. Their superposition reveals a 
dramatically different orientation for Nup133NTD and slightly different orientations of the Nup133 and 




Interactions mediating inter-spoke assembly. (A) The outer ring inter-spoke interface is shown in 
surface representation, but with Nup188 removed for clarity. Contacts observed between CNCs from 
different spokes are indicated by arrows and numbered from 1 to 4, corresponding to the contacts 
described in the text. (B) The same view as in panel (A), but with Nup188 also shown in a surface 
representation. Contacts observed between Nup188 and the CNCs at the inter-spoke interface are 
indicated by arrows and numbered from 5 to 8, corresponding to the contacts described in the text. An 
arrow highlights the Nic96R2 binding site on Nup188. (C) Schematic of the inter-spoke interface, from 
the same view as in panel (A). (D) The outer ring inter-spoke interface, shown in cartoon 
representation, ~180° rotated from the view in panel (A). Nup170 and Nup133 contact overlapping 
interfaces on proximal and distal Nup120 molecules. (E) Schematic of the outer ring inter-spoke 




Oligomerization of the CNC. (A) The CNC forms oil droplets in the presence of the unstructured N-
terminal extension (NTE) of Nup133. The CNC-hexamer was labeled with Bodipy and various other 
nucleoporins were labeled with Alexa-647 and tested for their ability to form oil droplets. Nup170 
incorporates CNC oil droplets, but this incorporation is ablated by deletion of C-terminal helices. Tested 
protein combinations are indicated in the table and shown schematically on the right. All experiments 
were repeated at least three times. (B, C) SEC-MALS profiles of nucleoporin complexes are shown 
individually (blue or red) and after their preincubation (green). There is a weak interaction between 
Nup120•Nup37•ELYS and Nup84•Nup133 only in the presence of the NTE of Nup133. SEC profiles 
were obtained using a Superose 6 10/300 GL column. Measured molecular masses are indicated for 
the peak fractions. Gray bars indicate fractions that were resolved on SDS-PAGE gels and visualized 





Overall nucleoporin folds are evolutionarily conserved. Structural comparison of C. thermophilum 
Nup170 and Nic96 complexes reported here and previously determined apo S. cerevisiae crystal 
structures, revealing extensive evolutionary conservation of the overall folds. (A) Nup170NTD•Nup53R3 
(left), scNup157NTD (PDB ID 4MHC; middle), and their superposition (right) are shown in cartoon 
representation (21). (B) Nup170CTDNup145NR3 (left), scNup170CTD (PDB ID 3I5P; middle), and their 
superposition (right) are shown in cartoon representation (23). (C) Nic96SOL•Nup53R2 (left), scNic96SOL 




Binding pockets on scNup157 and scNic96 for scNup53 are evolutionarily conserved. (A, B) 
SEC interaction experiments were performed with constructs of S. cerevisiae Nup157NTD and Nup53 
homologous to the crystallized Nup170NTD•Nup53R3 complex and with a mutant Nup157NTD construct in 
which a conserved F214 residue in the Nup53 binding pocket was mutated to alanine. SEC profiles of 
nucleoporins are shown individually (blue and red) and after their preincubation (green). (C) A close-up 
view of the Nup170NTD•Nup53R3 complex, same as Fig. 3C. (D) A close-up view of the corresponding 
surface of scNup157 (PDB ID 4MHC) reveals that the hydrophobic binding pocket for Nup53R3 is intact 
(21). An asterisk highlights the scNup157NTD mutant that abolished the interaction with scNup53. (E, F) 
Interaction experiments were performed with fragments of S. cerevisiae Nic96SOL and Nup53 
homologous to the crystallized Nic96SOL•Nup53R2 complex and with mutant scNic96SOL in which 
conserved hydrophobic residues within the Nup53 binding pocket were mutated to alanine. SEC 
profiles of nucleoporins are shown individually (blue and red) and after their preincubation (green). (G) 
A close-up view of the Nic96SOL•Nup53R2 complex, same as Fig. 4C. (H) A close-up view of the 
corresponding surface of scNic96SOL (PDB ID 2RFO) reveals that the hydrophobic groove that 
recognizes Nup53R2 is intact (24). Asterisks highlight the scNic96SOL mutants that abolished the 
interaction with scNup53. All SEC profiles were obtained using a Superdex 200 10/300 GL column. 





Binding pockets on scNup157 and scNup170 for the Nup145N paralogs scNup100 and 
scNup145N are conserved. (A-F) SEC profiles of nucleoporins or nucleoporin complexes are shown 
individually (blue and red) and after their preincubation (green). All SEC profiles were obtained using a 
Superdex 200 10/300 GL column. Gray bars indicate fractions that were resolved on SDS-PAGE gels 




Other Nup145N interactions are conserved in the three S. cerevisiae paralogs scNup100, 
scNup145N, and scNup116, but scNup116 only binds very weakly to scNup170CTD and 
scNup157CTD. (A-F) SEC profiles of nucleoporins or nucleoporin complexes are shown individually 
(blue and red) and after their preincubation (green). All SEC profiles were obtained using a Superdex 
200 10/300 GL column. Gray bars indicate fractions that were resolved on SDS-PAGE gels and 




All three S. cerevisiae Nup145N paralogs bind to scNup192NTD, but none bind to scNup188. (A-F) 
SEC profiles of nucleoporins or nucleoporin complexes are shown individually (blue and red) and after 
their preincubation (green). All SEC profiles were obtained using a Superdex 200 10/300 GL column. 





scNup145N and scNup100 bind to scNup170CTD and scNup157CTD in a mutually exclusive 
fashion. (A, B) scNup145N and scNup100 bind to scNup170CTD in a mutually exclusive fashion and 
scNup145N outcompetes scNup100. (C, D) scNup157CTD and scNup170CTD bind to scNup145N in a 
mutually exclusive fashion. SEC profiles of nucleoporins or nucleoporin complexes are shown 
individually (blue and red) and after their preincubation (green). All SEC profiles were obtained using a 
Superdex 200 10/300 GL column. Gray bars indicate fractions that were resolved on SDS-PAGE gels 
and visualized by Coomassie staining. (E) Close-up view of the Nup170CTD•Nup145NR3 complex. (F) 
Close-up view of the corresponding surface in scNup170CTD (PDB ID 3I5P) revealed that both 
hydrophobic binding pockets for Nup145NR3 are conserved (23). The conserved residue, F1308, which 
was mutated in the interaction experiments in figs. S47 and S48 is indicated by an asterisk. (G) 
Summary of the results of interaction experiments performed with S. cerevisiae Nup145N homologs. 
Check marks indicate complexes that can form in SEC experiments, crosses indicate complexes that 
do not form, and dashes indicate complexes that were not tested. (H) Summary of the results of 
interaction experiments performed with S. cerevisiae Nup53. Check marks indicate complexes that can 
form in SEC experiments, crosses indicate complexes that do not form, and dashes indicate complexes 




Purification protocol for Nup120•Nup37•ELYS•Nup85 hetero-tetramer. Domain boundaries of the 
purified nucleoporins are shown with black lines indicating the construct boundaries. Sequential 
chromatography purification steps are shown from top to bottom with the employed columns indicated. 
Gray bars indicate fractions that were resolved on SDS-PAGE gels and visualized by Coomassie 
staining. Pooled fractions are indicated with a black bar above the SDS-PAGE gels. For details of the 




Purification protocol for the Sec13•Nup145C hetero-dimer. Domain boundaries of the purified 
nucleoporins are shown with black lines indicating the construct boundaries. Sequential 
chromatography purification steps are shown from top to bottom with the employed columns indicated. 
Gray bars indicate fractions that were resolved on SDS-PAGE gels and visualized by Coomassie 
staining. Pooled fractions are indicated with a black bar above the SDS-PAGE gels. For details of the 




Purification protocol for the Nup84•Nup133 hetero-dimer. Domain boundaries for the purified 
proteins are shown above with black lines indicating the construct boundaries. Sequential steps of 
purification via chromatography are shown from top to bottom, with the fractions pooled for the 
subsequent step highlighted in grey. SDS-PAGE gels for each step of the purification are shown next to 




Purification protocol for the CNT•Nic96 hetero-tetramer. Domain boundaries of the purified 
nucleoporins are shown with black lines indicating the construct boundaries. Sequential 
chromatography purification steps are shown from top to bottom with the employed columns indicated. 
Gray bars indicate fractions that were resolved on SDS-PAGE gels and visualized by Coomassie 
staining. Pooled fractions are indicated with a black bar above the SDS-PAGE gels. For details of the 




Purification protocol for Nup192. Domain boundaries of the purified nucleoporins are shown with 
black lines indicating the construct boundaries. Sequential chromatography purification steps are 
shown from top to bottom with the employed columns indicated. Gray bars indicate fractions that were 
resolved on SDS-PAGE gels and visualized by Coomassie staining. Pooled fractions are indicated with 




Purification protocol for Nup188. Domain boundaries of the purified nucleoporins are shown with 
black lines indicating the construct boundaries. Sequential chromatography purification steps are 
shown from top to bottom with the employed columns indicated. Gray bars indicate fractions that were 
resolved on SDS-PAGE gels and visualized by Coomassie staining. Pooled fractions are indicated with 




Purification protocol for Nup170. Domain boundaries of the purified nucleoporins are shown with 
black lines indicating the construct boundaries. Sequential chromatography purification steps are 
shown from top to bottom with the employed columns indicated. Gray bars indicate fractions that were 
resolved on SDS-PAGE gels and visualized by Coomassie staining. Pooled fractions are indicated with 




Purification protocol for Nup53. Domain boundaries of the purified nucleoporins are shown with black 
lines indicating the construct boundaries. Sequential chromatography purification steps are shown from 
top to bottom with the employed columns indicated. Gray bars indicate fractions that were resolved on 
SDS-PAGE gels and visualized by Coomassie staining. Pooled fractions are indicated with a black bar 




Purification protocol for Nup145N. Domain boundaries of the purified nucleoporins are shown with 
black lines indicating the construct boundaries. Sequential chromatography purification steps are 
shown from top to bottom with the employed columns indicated. Gray bars indicate fractions that were 
resolved on SDS-PAGE gels and visualized by Coomassie staining. Pooled fractions are indicated with 
a black bar above the SDS-PAGE gels. For details of the buffer conditions see Table S2. 
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1 Nup82 NTD 1-595 pET28a-PreS NdeI, NotI GPH none 18 °C / 18 hours 




NdeI, BamHI GPHMHHHHHH none 
37 °C / 2 hours Nup37 1-610 NdeI, BamHI Q none 
ELYS 1-299 BamHI, NotI S none 
4 Nup85 230-1169 pET24a NdeI, BamHI MGHHHHHH none 37 °C / 2 hours 
5 Sec13 1-309 pETMCN NdeI, BamHI Q none 
23 °C / 18 hours; 
coexpressed with 
Nup145C 
6 Nup145C 1-800 pET-MCN-SUMO NcoI, NotI S none 
23 °C / 18 hours; 
coexpressed with 
Sec13 
7 Nup84 1-939 pET24a NdeI, BamHI MGHHHHHH none 
23 °C / 18 hours; 
coexpressed with 
Nup133 
8 Nup133 1-1364 pET-MCN-SUMO EcoRI, HindIII SEF none 
23 °C / 18 hours; 
coexpressed with 
Nup84 
9 Nup133 ∆NTE 105-1364 pET-MCN-SUMO EcoRI, HindIII SEF none 
23 °C / 18 hours; 
coexpressed with 
Nup84 
10 Nup53 1-361 pET28a-SUMO BamHI, XhoI S LEHHHHHH 23 °C / 18 hours 
11t Nup53 RRM 133-253 pET28a-PreS NdeI, XhoI GPHM none 23 °C / 18 hours 
12 Nup53 R2 69-90 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
13t Nup53 31-84 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
14 Nup53 R1 31-67 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
15 Nup53 1-90 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
16 Nup53 R3 329-361 pGEX-6P-1 BamHI, NotI not cleaved none 37 °C / 2 hours 
17 Nup53 R3 (F334A) 329-361 pGEX-6P-1 BamHI, NotI not cleaved none 37 °C / 2 hours 
18 Nup53 R3 (I338A) 329-361 pGEX-6P-1 BamHI, NotI not cleaved none 37 °C / 2 hours 
19 Nup53 R3 (R342A) 329-361 pGEX-6P-1 BamHI, NotI not cleaved none 37 °C / 2 hours 
20 Nup53 R3 (K343A) 329-361 pGEX-6P-1 BamHI, NotI not cleaved none 37 °C / 2 hours 
21 Nup53 R3 (L346A) 329-361 pGEX-6P-1 BamHI, NotI not cleaved none 37 °C / 2 hours 
22 Nup53 R3 (L347A) 329-361 pGEX-6P-1 BamHI, NotI not cleaved none 37 °C / 2 hours 
23 Nup53 R3 (E350A) 329-361 pGEX-6P-1 BamHI, NotI not cleaved none 37 °C / 2 hours 
24 Nup53 R3 (E351A) 329-361 pGEX-6P-1 BamHI, NotI not cleaved none 37 °C / 2 hours 
25 Nup53 R3 (L353A) 329-361 pGEX-6P-1 BamHI, NotI not cleaved none 37 °C / 2 hours 
26 Nup53 R3 (L354A) 329-361 pGEX-6P-1 BamHI, NotI not cleaved none 37 °C / 2 hours 
27 Nup170 74-1402 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
28 Nup170 ∆C 74-1037 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
29t Nup170 SOL 575-1402 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
30 Nup170 CTD 851-1402 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
31t Nup170 CTD (∆TLR) 851-1402 (∆1375-1377) pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
32t Nup170 NTD 74-827 (∆293-305) pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
33t Nup170 NTD 74-843 (∆293-305) pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
34 Nup170 NTD (F199A) 74-843 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
35 Nup170 NTD (Y235A) 74-843 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
36 Nup170 NTD (V241A) 74-843 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
37 Nup170 NTD (W280A) 74-843 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
38t Nup170 CTD 851-1416 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
39 Nup170 NTD (F281A) 74-843 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
40 Nup170 NTD (R284A) 74-843 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
41 Nup170 NTD (I203A) 74-843 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
42 Nup170 NTD (M239A) 74-843 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
43 Nup170 NTD (L218A) 74-843 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
44 Nup170 NTD (E214A) 74-843 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
45 Nup170 NTD (E181A) 74-843 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
46 Nup170 CTD (Y1050A) 851-1402 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
47 Nup170 CTD (V1062A) 851-1402 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
48 Nup170 CTD (L1066A) 851-1402 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
49 Nup170 CTD (E1110A) 851-1402 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
50 Nup170 CTD (L1111A) 851-1402 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
51 Nup170 CTD (I1131A) 851-1402 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
52 Nup170 CTD (I1147A) 851-1402 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
53 Nup170 CTD (Y1164A) 851-1402 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
54 Nup170 CTD (F1171A) 851-1402 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
55 Nup170 CTD (F1154A) 851-1402 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 
56 Nup170 CTD (Y1157A) 851-1402 pET28a-SUMO BamHI, NotI S none 37 °C / 2 hours 


















58 Nup145N 606-993 pET28a-SUMO BamHI, NotI S none 23 °C / 18 hours 
59t Nup145N APD 858-993 pET28a-PreS NdeI, XhoI GPHM none 23 °C / 18 hours 
60t Nup145N APD (T994A) •Nup145C N 858-1000 pET28a-PreS NdeI, XhoI GPHM none 23 °C / 18 hours 
61 Nup145N R1 606-683 pET28a-SUMO BamHI, NotI S AAALEHHHHHH 37 °C / 2 hours 
62 Nup145N 606-750 pET28a-SUMO BamHI, NotI S AAALEHHHHHH 37 °C / 2 hours 
63 Nup145N 649-750 pET28a-SUMO BamHI, NotI S AAALEHHHHHH 37 °C / 2 hours 
64 Nup145N R3 729-750 pGEX-6P-1 BamHI, NotI not cleaved none 18 °C / 18 hours 
65 Nup145N R3 (L733A) 729-750 pGEX-6P-1 BamHI, NotI not cleaved none 18 °C / 18 hours 
66 Nup145N R3 (V734A) 729-750 pGEX-6P-1 BamHI, NotI not cleaved none 18 °C / 18 hours 
67 Nup145N R3 (I735A) 729-750 pGEX-6P-1 BamHI, NotI not cleaved none 18 °C / 18 hours 
68 Nup145N R3 (M739A) 729-750 pGEX-6P-1 BamHI, NotI not cleaved none 18 °C / 18 hours 
69 Nup145N R3 (D742A) 729-750 pGEX-6P-1 BamHI, NotI not cleaved none 18 °C / 18 hours 
70 Nup145N R3 (L743A) 729-750 pGEX-6P-1 BamHI, NotI not cleaved none 18 °C / 18 hours 
71 Nup145N R3 (F744A) 729-750 pGEX-6P-1 BamHI, NotI not cleaved none 18 °C / 18 hours 
72 Avi-Nup192 1-1756 pET28a-PreS NdeI, NotI GPLMSGLNDIFEAQKIEWHEGSAGGSGH none 37 °C / 2 hours 
73t Nup192 ∆HEAD 153-1756 (∆167-184, replaced with GSGS) pET28a-PreS NdeI, NotI GPHM none 37 °C / 2 hours 
74 Nup192 NTD 1-958 pET28a-PreS NdeI, NotI GPH none 37 °C / 2 hours 
75 Nup192 CTD 921-1756 pET28a-PreS NdeI, NotI GPHM none 23 °C / 18 hours 
76 Nup192 TAIL 1397-1756 pET28a-PreS NdeI, NotI GPHM none 37 °C / 2 hours 
77 Nic96 110-1112 pET28a-SUMO BamHI, NotI S AAALEHHHHHH 18 °C / 18 hours 
78t Nic96 SOL 391-1112 pET28a-SUMO BamHI, NotI S none 18 °C / 18 hours 
79 Nic96 R2∆2 274-301 pET-MCN-SUMO BamHI, NotI S none 
37 °C / 2 hours 
coexpressed with 
Nup188 TAIL 
80 Nic96 R2∆4 286-301 pET-MCN-SUMO BamHI, NotI S none 37 °C / 2 hours 
81 Nic96 R2 262-301 pET-MCN-SUMO BamHI, NotI S none 37 °C / 2 hours 
82 Nic96 R2 (F275A) 262-301 pET-MCN-SUMO BamHI, NotI S none 37 °C / 2 hours 
83 Nic96 R2 (D276A) 262-301 pET-MCN-SUMO BamHI, NotI S none 37 °C / 2 hours 
84 Nic96 R2 (F278A) 262-301 pET-MCN-SUMO BamHI, NotI S none 37 °C / 2 hours 
85 Nic96 R2 (N282A) 262-301 pET-MCN-SUMO BamHI, NotI S none 37 °C / 2 hours 
86 Nic96 R2 (L285A) 262-301 pET-MCN-SUMO BamHI, NotI S none 37 °C / 2 hours 
87 Nic96 R2 (W287A) 262-301 pET-MCN-SUMO BamHI, NotI S none 37 °C / 2 hours 
88 Nic96 R2 (I294A) 262-301 pET-MCN-SUMO BamHI, NotI S none 37 °C / 2 hours 
89 Nic96 R2 (F298A) 262-301 pET-MCN-SUMO BamHI, NotI S none 37 °C / 2 hours 
90 Nic96 SOL (L715A) 391-1112 pET28a-SUMO BamHI, NotI S none 18 °C / 18 hours 
91 Nic96 SOL (V655A/W658A) 391-1112 pET28a-SUMO BamHI, NotI S none 18 °C / 18 hours 
92 Nic96 SOL (F697A) 391-1112 pET28a-SUMO BamHI, NotI S none 18 °C / 18 hours 
93 Nup188 1-1858 pET28a-PreS AseI, BamHI GPHN none 23 °C / 18 hours 
94 Nup188 NTD 1-1134 pET28a-PreS AseI, BamHI GPHN none 23 °C / 18 hours 




NcoI, NotI None none 18 °C / 18 hours 
coexpressed with 
Nup49 Nup57 74-319 NdeI, XhoI M none 
97 Nup49 246-470 pET28a-SUMO BamHI, NotI S none 
18 °C / 18 hours 
coexpressed with 
Nsp1 and Nup57 
98 hsNup155 CTD 870-1391 pET28a-PreS NdeI, NotI GPHM none 37 °C / 2 hours 
99 hsNup98 596-617 pGEX-6P-1 BamHI, NotI not cleaved none 23 °C / 18 hours 
100 hsNup98 (S608E/S612E) 596-617 pGEX-6P-1 BamHI, NotI not cleaved none 23 °C / 18 hours 
101 scNup159 T 1425-1460 pETDuet1 NcoI, NotI GPHM none 18 °C / 16 hours scNup82 NTD 1-452 NdeI, XhoI none none 
102 scNup145C 1-712 pETDuet1 BamHI, NotI MGSSHHHHHHSQDP none 18 °C / 16 hours scSec13 1-297 NdeI, XhoI N/A none 
103 scNup53 374-460 pET28a-SUMO BamHI, NotI S none 18 °C / 16 hours 
104 scNup170 CTD 999-1502 pET28a-SUMO SacI, NotI SEFEL none 18 °C / 8 hours 
105 scNup170 CTD (F1308A) 999-1502 pET28a-SUMO SacI, NotI SEFEL none 18 °C / 8 hours 
106 scNup157 CTD 894-1391 pET28a-SUMO BamHI, NotI S none 18 °C / 16 hours 
107 scNup157 NTD 70-893 pGEX-6P-1 BamHI, NotI GPLGS none 18 °C / 8 hours 
108 scNup157 NTD (F214A) 70-893 pGEX-6P-1 BamHI, NotI GPLGS none 18 °C / 8 hours 
109 scNup100 571-959 pET28a-SUMO BamHI, NotI S none 18 °C / 16 hours 
110 scNup116 752-1113 pET28a-SUMO BamHI, NotI S none 18 °C / 16 hours 
111 scNup145N 210-605 pET28a-SUMO BamHI, NotI S none 18 °C / 16 hours 
112 scNup192 NTD 1-960 pET28a-PreS NdeI, NotI GPH none 21 °C / 8 hours 
113 scNic96 SOL (I432A/W435A/Y469A) 204-839 pET28a-SUMO BamHI, NotI S none 18 °C / 16 hours 
114 scNup53 1-240 pET28a-SUMO BamHI, NotI S none 18 °C / 16 hours 
115 scNup188 1-1655 pET28a-SUMO BamHI, NotI S none 21 °C / 16 hours 
116 Nup145N PreS 606-993 pET28a-SUMO BamHI, NotI S none 23 °C / 18 hours 
Proteins are from C. thermophilum unless otherwise noted 
t Constructs that were used for crystallization 
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4. MonoQ 10/100 GL 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. IEX-A2, pH 8.0, 5 mM β-ME / PreS 
3. Ni-A2, 5 mM β-ME 
4. IEX-A2, pH 8.0, 5 mM DTT 
5. SEC-A, 5 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 
3. Ni-B1, 5 mM β-ME 
4. IEX-B, pH 8.0, 5 mM DTT 
5. N/A 





4. MonoQ 10/100 GL 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. IEX-A2, pH 8.0, 5 mM β-ME / PreS 
3. Ni-A2, 5 mM β-ME 
4. IEX-A2, pH 8.0, 5 mM DTT 
5. SEC-A, 5 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 
3. Ni-B1, 5 mM β-ME 
4. IEX-B, pH 8.0, 5 mM DTT 
5. N/A 





4. HiTrap Q HP 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. Ni-A2, 5 mM β-ME / PreS 
3. Ni-A2, 5 mM β-ME 
4. IEX-A2, pH 8.0, 5 mM DTT 
5. SEC-A, 5 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 
3. Ni-B1, 5 mM β-ME 
4. IEX-B, pH 8.0, 5 mM DTT 
5. N/A 





4. MonoQ 10/100 GL 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. IEX-A2, pH 8.0, 5 mM β-ME / PreS 
3. Ni-A2, 5 mM β-ME 
4. IEX-A2, pH 8.0, 5 mM DTT 
5. SEC-A, 5 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 
3. Ni-B1, 5 mM β-ME 
4. IEX-B, pH 8.0, 5 mM DTT 
5. N/A 





4. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. Ni-A3, 5 mM β-ME / PreS 
3. Ni-A3, 5 mM β-ME 
4. SEC-C, 1 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 







4. HiTrap Q HP 
5. HiLoad Superdex 200 16/60 PG 
6. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. IEX-A2, pH 8.0, 5 mM β-ME / PreS 
3. Ni-A2, 5 mM β-ME 
4. IEX-A2, pH 8.0, 5 mM DTT 
5. SEC-A, 5 mM DTT 
6. SEC-A, 5 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 
3. Ni-B1, 5 mM β-ME 
4. IEX-B, pH 8.0, 5 mM DTT 
5. N/A 
6. N/A 





4. HiTrap Q HP 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. Ni-A2, 5 mM β-ME / PreS 
3. Ni-A2, 5 mM β-ME 
4. IEX-A2, pH 8.0, 5 mM DTT 
5. SEC-A, 5 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 
3. Ni-B1, 5 mM β-ME 
4. IEX-B, pH 8.0, 5 mM DTT 
5. N/A 





4. HiTrap Q HP 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. Ni-A2, 5 mM β-ME / ULP1 
3. Ni-A2, 5 mM β-ME 
4. IEX-A2, pH 8.0, 5 mM DTT 
5. SEC-A, 5 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 
3. Ni-B1, 5 mM β-ME 
4. IEX-B, pH 8.0, 5 mM DTT 
5. N/A 
Nic96 SOLt 




2. HiPrep 26/20 Desalting/Cleavage  
3. Ni-NTA 
4. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. IEX-A2, pH 8.0, 5 mM β-ME / ULP1 
3. Ni-A2, 5 mM β-ME 
4. SEC-A, 5 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 
3. Ni-B1, 5 mM β-ME 
4. N/A 
Nup170* Individual 
(#27) 1. Ni-NTA 
2. Dialysis/Cleavage 
3. Ni-NTA 
4. HiTrap Q HP 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME, 5 % Glycerol 
2. Ni-A3, 5 mM β-ME, 5 % Glycerol / ULP1 
3. Ni-A3, 5 mM β-ME, 5 % Glycerol 
4. IEX-A4, pH 8.0, 5 mM DTT, 5 % Glycerol 
5. SEC-C, 5 mM DTT, 5 % Glycerol 
1. Ni-B1, 5 mM β-ME, 5 % Glycerol 
2. N/A 
3. Ni-B1, 5 mM β-ME, 5 % Glycerol 
4. IEX-B, pH 8.0, 5 mM DTT, 5 % Glycerol 
5. N/A 
Nup170 SOLt Individual 
(#29) 1. Ni-NTA 
2. Dialysis/Cleavage (48 hr) 
3. Ni-NTA 
4. HiTrap Q HP 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME,  
2. Ni-A3, 5 mM β-ME / ULP1 
3. Ni-A3, 5 mM β-ME 
4. IEX-A4, pH 8.0, 5 mM DTT 
5. SEC-C, 5 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 
3. Ni-B1, 5 mM β-ME 
4. IEX-B, pH 8.0, 5 mM DTT 
5. N/A 
Nup170 NTDt 







4. HiTrap Q HP 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME, 5 % Glycerol 
2. Ni-A3, 5 mM β-ME, 5 % Glycerol / ULP1 
3. Ni-A3, 5 mM β-ME, 5 % Glycerol 
4. IEX-A2, pH 8.0, 5 mM DTT, 5 % Glycerol 
5. SEC-C, 5 mM DTT, 5 % Glycerol 
1. Ni-B1, 5 mM β-ME, 5 % Glycerol 
2. N/A 
3. Ni-B1, 5 mM β-ME, 5 % Glycerol 
4. IEX-B, pH 8.0, 5 mM DTT, 5 % Glycerol 
5. N/A 
Nup170 CTDt 





2. HiPrep 26/20 Desalting/Cleavage 
3. Ni-NTA 
4. HiTrap Q HP 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. Ni-A2, 5 mM β-ME / ULP1 
3. Ni-A2, 5 mM β-ME 
4. IEX-A2, pH 8.0, 5 mM DTT 
5. SEC-A, 5 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 
3. Ni-B1, 5 mM β-ME 
4. IEX-B, pH 8.0, 5 mM DTT 
5. N/A 
hsNup155 CTD Individual 
(#98) 
1. Ni-NTA 
2. HiPrep 26/20 Desalting/Cleavage 
3. Ni-NTA 
4. HiTrap Q HP 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME, 5 % Glycerol 
2. Ni-A3, 5 mM β-ME, 5 % Glycerol / PreS 
3. Ni-A3, 5 mM β-ME, 5 % Glycerol 
4. IEX-A3, pH 8.0, 5 mM DTT, 5 % Glycerol 
5. SEC-B, 5 mM DTT, 5 % Glycerol 
1. Ni-B1, 5 mM β-ME, 5 % Glycerol 
2. N/A 
3. Ni-B1, 5 mM β-ME, 5 % Glycerol 







3. HiTrap Q HP 
4. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME, 5 % Glycerol 
2. Ni-A3, 5 mM DTT, 5 % Glycerol / ULP1-PreS 
3. IEX-A4, pH 8.0, 5 mM DTT, 5 % Glycerol 
4. SEC-A,  5 mM DTT 
1. Ni-B1, 5 mM β-ME, 5 % Glycerol 
2. N/A 






3. HiTrap Q HP 
4. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. Ni-A2, 5 mM DTT / PreS 
3. IEX-A2, pH 8.0, 5 mM DTT 
4. SEC-A, 5 mM DTT 
1. Ni-B1, 5 mM β-ME, 5 % Glycerol 
2. N/A 








2. HiPrep 26/20 Desalting /Cleavage 
3. Ni-NTA 
4. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. Ni-A2, 5 mM β-ME / ULP1 
3. Ni-A2, 5 mM β-ME 
4. SEC-A, 5 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 



















2. Dialysis  
3. HiLoad Superdex 200 16/60 PG 
4. MonoQ 10/100 GL 
1. Ni-A1, 5 mM β-ME 
2. SEC-A, 5 mM DTT 
3. SEC-A, 5 mM DTT 
4. IEX-A2, pH 8.0, 5 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 
3. N/A 





2. Dialysis  
3. HiLoad Superdex 200 16/60 PG 
4. MonoQ 10/100 GL 
1. Ni-A1, 5 mM β-ME 
2. SEC-A, 5 mM DTT 
3. SEC-A, 5 mM DTT 
4. IEX-A2, pH 8.0, 5 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 
3. N/A 
4. IEX-B, pH 8.0, 5 mM DTT 
Nup145N* 




2. HiPrep 26/20 Desalting/Cleavage 
3. MonoS 5/50 GL 
4. HiLoad Superdex 75 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. IEX-A2, pH 7.0, 5 mM DTT / ULP1 
3. IEX-A2, pH 7.0, 5 mM DTT 
4. SEC-A, 5 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 
3. IEX-B, pH 7.0, 5 mM DTT 
4. N/A 





4. HiLoad Superdex 75 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. Ni-A2, pH 8.0, 5 mM β-ME / PreS 
3. Ni-A2, 5 mM β-ME 
4. SEC-A, 5 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 
3. Ni-B1, 5 mM β-ME 
4. N/A 
GST-Nup145N 
wild-type and mutants  
Individual 
(#64, 65-71) 1. GST Affinity 2. HiTrap Q HP 
3. HiLoad Superdex 200 16/60 PG 
1. GST-A, 5 mM DTT 
2. IEX-A2, pH 8.0, 5 mM DTT 
3. SEC-A, 5 mM DTT 
1. GST-B, 5mM DTT 
2. IEX-B, pH 8.0, 5 mM DTT 
3. N/A 
GST-hsNup98 
wild-type and mutant 
Individual 
(#99, 100) 1. GST Affinity 2. HiTrap Q HP 
3. HiLoad Superdex 200 16/60 PG 
1. GST-A, 5 mM DTT 
2. IEX-A2, pH 8.0, 5 mM DTT 
3. SEC-A, 5 mM DTT 
1. GST-B, 5mM DTT 







2. HiPrep 26/20 Desalting /Cleavage 
3. Ni-NTA 
4. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. Ni-A2, 5 mM β-ME / ULP1 
3. Ni-A2, 5 mM β-ME 
4. SEC-A, 5 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 





2. HiPrep 26/20 Desalting/Cleavage 
3. Ni-NTA 
4. HiPrep 26/20 Desalting 
5. MonoS 5/50 GL 
6. HiLoad Superdex 75 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. Ni-A1, 5 mM β-ME / ULP1 
3. Ni-A1, 5 mM β-ME 
4. IEX-A2, pH 7.0, 5 mM DTT 
5. IEX-A2, pH 7.0, 5 mM DTT 
6. SEC-A, 5 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 
3. Ni-B1, 5 mM β-ME 
4. N/A 
5. EX-B, pH 7.0, 5 mM DTT 
6. N/A 




3. Ni-NTA  
4. HiLoad Superdex 75 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. Ni-A2, pH 8.0, 5 mM β-ME / PreS 
3. Ni-A2, 5 mM β-ME 
4. SEC-A, 5 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 







2. HiPrep 26/20 Desalting 
3. HiLoad Superdex 75 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. SEC-A, 5 mM DTT  
3. SEC-A, 5 mM DTT 




wild-type and mutants  
Individual 
(#16, 17-26) 
1. GST Affinity 
2. HiTrap Q HP 
3. HiLoad Superdex 200 16/60 PG 
1. GST-A, 5 mM DTT 
2. IEX-A2, pH 8.0, 5 mM DTT 
3. SEC-A, 5 mM DTT 
1. GST-B, 5mM DTT 






2. HiPrep 26/20 Desalting/Cleavage 
3. Ni-NTA 
4. HiTrap Q HP 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 4 mM β-ME 
2. Ni-A2, 4 mM β-ME / ULP1 
3. Ni-A2, 4 mM β-ME 
4. IEX-A2, pH 8.0, 5 mM DTT 
5. SEC-A, 5 mM DTT 
1. Ni-B1, 4 mM β-ME 
2. N/A 
3. Ni-B1, 4 mM β-ME 











4. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. Ni-A1, 5 mM β-ME/ PreS / ULP1 
3. Ni-A1, 5 mM β-ME 
4. SEC-A, 5 mM DTT 
1. Ni-B1, 4 mM β-ME 
2. N/A 
3. Ni-B1, 4 mM β-ME 
4. N/A 




3. HiTrap Q HP 
4. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. IEX-A1, pH 9.0, 1 mM DTT 
3. IEX-A1, pH 9.0, 1 mM DTT 
4. SEC-C, 1 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 
3. IEX-B, pH 9.0, 1 mM DTT 
4. N/A 




3. MonoQ 10/100 GL 
4. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. IEX-A2, pH 8.0, 1 mM DTT 
3. IEX-A2, pH 8.0, 1 mM DTT 
4. SEC-C, 1 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 









3. HiTrap Q HP 
4. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. IEX-A2, pH 8.0, 1 mM DTT 
3. IEX-A2, pH 8.0, 1 mM DTT 
4. SEC-C, 1 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 
3. IEX-B, pH 8.0, 1 mM DTT 
4. N/A 




3. HiTrap Q HP 
4. HiLoad Superdex 75 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. IEX-A2, pH 8.0, 1 mM DTT 
3. IEX-A2, pH 8.0, 1 mM DTT 
4. SEC-C, 1 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 
3. IEX-B, pH 8.0, 1 mM DTT 
4. N/A 




3. HiTrap Q HP 
4. HiLoad Superdex 75 16/60 PG 
1. Ni-A1, 5 mM β-ME 
2. IEX-A2, pH 8.0, 5 mM β-ME 
3. IEX-A2, pH 8.0, 1 mM DTT 
4. SEC-C, 1 mM DTT 
1. Ni-B1, 5 mM β-ME 
2. N/A 
3. IEX-B, pH 8.0, 1 mM DTT 
4. N/A 




3. HiTrap Q HP 
4. HiLoad Superdex 200 16/60 PG 
1. Ni-A4, 4 mM β-ME, 5 % Glycerol 
2. IEX-A3, pH 8.0, 4 mM β-ME, 5 % Glycerol 
3. IEX-A3, pH 8.0, 4 mM β-ME, 5 % Glycerol 
4. SEC-B, 5 mM DTT, 5 % Glycerol 
1. Ni-B1, 4 mM β-ME 
2. N/A 







4. HiTrap Q HP 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A4, 4 mM β-ME, 5 % Glycerol 
2. IEX-A3, pH 8.0, 4 mM β-ME, 5 % Glycerol / ULP1 
3. IEX-A3, pH 8.0, 4 mM β-ME 5 % Glycerol 
4. IEX-A3, pH 8.0, 4 mM β-ME 5 % Glycerol 
5. SEC-B, 5 mM DTT, 5 % Glycerol 
1. Ni-B1, 4 mM β-ME 
2. N/A 
3. Ni-B1, 4 mM β-ME  
4. IEX-B, pH 8.0, 4 mM β-ME 
5. N/A 




3. HiTrap Q HP 
4. HiLoad Superdex 200 16/60 PG 
1. Ni-A4, 4 mM β-ME, 5 % Glycerol 
2. IEX-A3, pH 8.0, 4 mM β-ME, 5 % Glycerol  
3. IEX-A3, pH 8.0, 4 mM β-ME, 5 % Glycerol 
4. SEC-B, 5 mM DTT, 5 % Glycerol 
1. Ni-B1, 4 mM β-ME 
2. N/A 
3. IEX-B, pH 8.0, 4 mM β-ME 
4. N/A 

















4. HiTrap Q HP 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A4, 4 mM β-ME, 5 % Glycerol 
2. IEX-A3, pH 8.0, 4 mM β-ME, 5 % Glycerol / ULP1 
3. IEX-A3, pH 8.0, 4 mM β-ME 5 % Glycerol 
4. IEX-A3, pH 8.0, 4 mM β-ME 5 % Glycerol 
5. SEC-B, 5 mM DTT, 5 % Glycerol 
1. Ni-B1, 4 mM β-ME 
2. N/A 
3. Ni-B1, 4 mM β-ME  







4. HiTrap Q HP 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A4, 4 mM β-ME, 5 % Glycerol 
2. IEX-A3, pH 8.0, 4 mM β-ME, 5 % Glycerol / ULP1 
3. IEX-A3, pH 8.0, 4 mM β-ME 5 % Glycerol 
4. IEX-A3, pH 8.0, 4 mM β-ME 5 % Glycerol 
5. SEC-B, 5 mM DTT, 5 % Glycerol 
1. Ni-B1, 4 mM β-ME 
2. N/A 
3. Ni-B1, 4 mM β-ME 






3. HiTrap Q HP 
4. HiLoad Superdex 200 16/60 PG 
1. Ni-A4, 4 mM β-ME, 5 % Glycerol 
2. IEX-A3, pH 8.0, 4 mM β-ME, 5 % Glycerol 
3. IEX-A3, pH 8.0, 4 mM β-ME, 5 % Glycerol 
4. SEC-B, 5 mM DTT, 5 % Glycerol 
1. Ni-B1, 4 mM β-ME 
2. N/A 







4. HiTrap Q HP 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A4, 4 mM β-ME, 5 % Glycerol 
2. IEX-A2, pH 8.0, 4 mM β-ME, 5 % Glycerol / ULP1 
3. IEX-A2, pH 8.0, 4 mM β-ME 5 % Glycerol 
4. IEX-A2, pH 8.0, 4 mM β-ME 5 % Glycerol 
5. SEC-A, 5 mM DTT, 5 % Glycerol 
1. Ni-B1, 4 mM β-ME 
2. N/A 
3. Ni-B1, 4 mM β-ME 
4. IEX-B, pH 8.0, 4 mM β-ME 
5. N/A 





4. HiTrap Q HP 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A4, 4 mM β-ME, 5 % Glycerol 
2. IEX-A2, pH 8.0, 4 mM β-ME, 5 % Glycerol / PreS 
3. IEX-A2, pH 8.0, 4 mM β-ME 5 % Glycerol 
4. IEX-A2, pH 8.0, 4 mM β-ME 5 % Glycerol 
5. SEC-A, 5 mM DTT, 5 % Glycerol 
1. Ni-B1, 4 mM β-ME 
2. N/A 
3. Ni-B1, 4 mM β-ME 
4. IEX-B, pH 8.0, 4 mM β-ME 
5. N/A 
scNup170 CTD 






4. HiTrap Q HP 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A4, 4 mM β-ME, 5 % Glycerol 
2. IEX-A4, pH 8.0, 4 mM β-ME, 5 % Glycerol / ULP1 
3. IEX-A4, pH 8.0, 4 mM β-ME 5 % Glycerol 
4. IEX-A4, pH 8.0, 4 mM β-ME 5 % Glycerol 
5. SEC-C, 5 mM DTT, 5 % Glycerol 
1. Ni-B1, 4 mM β-ME 
2. N/A 
3. Ni-B1, 4 mM β-ME  
4. IEX-B, pH 8.0, 4 mM β-ME 
5. N/A 




3. HiTrap Q HP 
4. HiLoad Superdex 200 16/60 PG 
1. Ni-A4, 4 mM β-ME, 5 % Glycerol 
2. IEX-A4, pH 8.0, 4 mM β-ME, 5 % Glycerol 
3. IEX-A4, pH 8.0, 4 mM β-ME 5 % Glycerol 
4. SEC-C, 5 mM DTT, 5 % Glycerol 
1. Ni-B1, 4 mM β-ME 
2. N/A 
3. IEX-B, pH 8.0, 4 mM β-ME 
4. N/A 





4. HiTrap Q HP 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A4, 4 mM β-ME, 5 % Glycerol 
2. IEX-A4, pH 8.0, 4 mM β-ME, 5 % Glycerol / ULP1 
3. IEX-A4, pH 8.0, 4 mM β-ME 5 % Glycerol 
4. IEX-A4, pH 8.0, 4 mM β-ME 5 % Glycerol 
5. SEC-C, 5 mM DTT, 5 % Glycerol 
1. Ni-B1, 4 mM β-ME 
2. N/A 
3. Ni-B1, 4 mM β-ME  
4. IEX-B, pH 8.0, 4 mM β-ME 
5. N/A 




3. HiTrap Q HP 
4. HiLoad Superdex 200 16/60 PG 
1. Ni-A4, 4 mM β-ME, 5 % Glycerol 
2. IEX-A4, pH 8.0, 4 mM β-ME, 5 % Glycerol 
3. IEX-A4, pH 8.0, 4 mM β-ME 5 % Glycerol 
4. SEC-C, 5 mM DTT, 5 % Glycerol 
1. Ni-B1, 4 mM β-ME 
2. N/A 










4. HiTrap Q HP 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A4, 4 mM β-ME, 5 % Glycerol 
2. IEX-A2, pH 8.0, 4 mM β-ME, 5 % Glycerol / ULP1 
3. IEX-A2, pH 8.0, 4 mM β-ME 5 % Glycerol 
4. IEX-A2, pH 8.0, 4 mM β-ME 5 % Glycerol 
5. SEC-A, 5 mM DTT, 5 % Glycerol 
1. Ni-B1, 4 mM β-ME 
2. N/A 
3. Ni-B1, 4 mM β-ME  








4. HiTrap Q HP 
5. HiLoad Superdex 200 16/60 PG 
1. Ni-A4, 4 mM β-ME, 5 % Glycerol 
2. IEX-A2, pH 8.0, 4 mM β-ME, 5 % Glycerol / ULP1 
3. IEX-A2, pH 8.0, 4 mM β-ME 5 % Glycerol 
4. IEX-A2, pH 8.0, 4 mM β-ME 5 % Glycerol 
5. SEC-A, 5 mM DTT, 5 % Glycerol 
1. Ni-B1, 4 mM β-ME 
2. N/A 
3. Ni-B1, 4 mM β-ME  







2. HiPrep 26/20 Desalting/Cleavage 
3. HiLoad Superdex 200 16/60 PG 
1. Ni-A1, 4 mM β-ME 
2. SEC-A, 5 mM DTT / ULP1 
3. SEC-A, 5 mM DTT 







3. HiTrap Q HP 
4. HiLoad Superdex 75 16/60 PG 
1. Ni-A1, 4 mM β-ME 
2. IEX-A1, pH 8.0, 5 mM DTT 
3. IEX-A1, pH 8.0, 5 mM DTT 
4. SEC-A, 5 mM DTT 
1. Ni-B1, 4 mM β-ME 
2. N/A 
3. IEX-B, pH 8.0, 5 mM DTT 
4. N/A 
scNup157 NTD 
wild-type and mutant 
Individual 





(#77, 96, 97) 
co-lysis 
Detailed description in SI methods   
t Constructs that were used for crystallization 
* Detailed purification provided in supplementary figures 
 
Ni-A1: 20 mM TRIS (pH 8.0), 500 mM NaCl, 20 mM imidazole 
Ni-A2: 20 mM TRIS (pH 8.0), 100 mM NaCl, 20 mM imidazole 
Ni-A3: 20 mM TRIS (pH 8.0), 200 mM NaCl, 20 mM imidazole 
Ni-A4: 75 mM TRIS (pH 8.0), 500 mM NaCl, 20 mM imidazole 
Ni-B1: 20 mM TRIS (pH 8.0), 500 mM NaCl, 500 mM imidazole 
Ni-B2: 20 mM TRIS (pH 8.0), 100 mM NaCl, 500 mM imidazole 
 
GST-A: 20 mM TRIS (pH 8.0), 200 mM NaCl 
GST-B: 20 mM TRIS (pH 8.0), 200 mM NaCl, 20 mM glutathione 
 
IEX-A1: 20 mM TRIS, 50 mM NaCl 
IEX-A2: 20 mM TRIS, 100 mM NaCl 
IEX-A3: 20 mM TRIS, 150 mM NaCl 
IEX-A4: 20 mM TRIS, 200 mM NaCl 
IEX-B: 20 mM TRIS, 2.0 M NaCl 
 
SEC-A: 20 mM TRIS (pH 8.0), 100 mM NaCl 
SEC-B: 20 mM TRIS (pH 8.0), 150 mM NaCl 
SEC-C: 20 mM TRIS (pH 8.0), 200 mM NaCl 
149
 Table S3. 
SEC-MALS analysis 





fig. S3A Nup192Nup145NNup53 250 278  
Nic96CNT (Nic96Nup57Nup49Nsp1) 160 187  
IRCNup53 (Nup192Nic96Nup145NNup53CNT) 380 465 conc. dependent 
fig. S3B IRCNup53 (Nup192Nic96Nup145NNup53CNT) 335 423  
Nup188 180 204  




(Nup120Nup37ELYSNup85Sec13Nup145CNup145N) 482 507 
 
Nup192Nic96Nup53CNT 335 423  
CNC-hexamerIRCNup53 654 930 conc. dependent 
Fig. 1E 
fig. S4B 
CNC-hexamer (Nup120Nup37ELYSNup85Sec13Nup145C) 438 465  
Nup192Nic96Nup53CNT 335 423  
CNC-hexamer + IRCNup53 430 888 no interaction 
Fig. 1F 
fig. S4C 
CNC-hexamerNup145N 466 507  
Nup188Nic96Nup53CNT 523 431  
CNC-hexamerNup188Nic96Nup145NNup53CNT 1220 938 superstoichiometric 
Fig. 1G 
fig. S4D 
CNC-hexamer 428 465  
Nup188Nic96Nup53CNT 523 431  
CNC-hexamer + Nup188Nic96Nup53CNT 507 896 no interaction 
fig. S5A CNC-hexamer 428 465  
Nup145N 40 42  
CNC-hexamerNup145N 508 507 stoichiometric 
fig. S5B CNC-hexamer 428 465  
Nup145N APD 17 15  
CNC-hexamerNup145N APD 447 480 stoichiometric 
fig. S5C CNC-hexamer 428 465  
Nup145N PreS 36 / 15 27 / 15  
CNC-hexamerNup145N APD + Nup145N MID 690 480 superstoichiometric 
fig. S6A CNC-hexamer 428 465  
Nup82 NTDNup159 TNup145N 112 122  
CNC-hexamerNup145N + Nup82 NTDNup159 T 579 587 stoichiometric 
fig. S6B Nup188Nic96Nup53CNT 523 431  
Nup82 NTDNup159 TNup145N 126 122  
Nup188Nic96Nup145NNup53CNT + Nup82 NTDNup159 T 670 553 superstoichiometric 
Fig. 2A 
fig. S7A 
Nup192 176 196  
Nup188 180 204  
Nup170 132 147  
Nic96 SOL 73 81  
Nup192 + Nup188 + Nup170 + Nic96 SOL 174 628 no interaction 
Fig. 2B 
fig. S7B 
Nup192 + Nup170 + Nic96 SOL 161 / 93 172a / 81  
Nup53 + Nup145N 52 41a  
Nup192Nup170Nic96 SOLNup53Nup145N 528 506 stoichiometric 
Fig. 2C 
fig. S7C 
Nup188 + Nup170 + Nic96 SOL 165 / 87  176a / 81  
Nup53 + Nup145N 52 41a  
Nup188 + Nup170 + Nic96 SOL + Nup53 + Nup145N 242 512 weak interaction 
Fig. 2D 
fig. S8A 
Nic96 SOL  72 81  
Nup53 40 40  
Nic96 SOLNup53 146 121 superstoichiometric 
Fig. 2D 
fig. S8B 
Nup170 145 147  
Nup53 35 40  
Nup170Nup53 197 187 stoichiometric 
Fig. 2D 
fig. S8C 
Nup188 188 204  
Nup53 40 40  
Nup188 + Nup53 188 244 weak interaction 
Fig. 2D 
fig. S8D 
Nup192 178 196  
Nup53 40 40  
Nup192Nup53 223 236 stoichiometric 
Fig. 2D 
fig. S8E 
CNT (Nup57, Nup49, Nsp1) 70 77  
Nup53 38 40  
CNT + Nup53 73 117 weak interaction 
Fig. 2E 
fig. S9A 
Nup170 145 147  
Nup145N 42 42  
Nup170Nup145N 196 189 stoichiometric 
Fig. 2E 
fig. S9B 
Nup188 189 204  
Nup145N 40 42  
Nup188Nup145N 216 246 stoichiometric 
Fig. 2E 
fig. S9C 
Nup192  178 196  
Nup145N 40 42  
Nup192Nup145N 265 238 superstoichiometric 
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Nup170Nup53 154 187  
Nic96 SOL  70 81  
Nup170Nup53Nic96 SOL 208 268 stoichiometric 
Fig. 2D 
fig. S10B 
Nup170Nup53 154 187  
Nup188 194 204  
Nup170Nup53 + Nup188  188 391 no interaction 
Fig. 2D 
fig. S10C 
Nup170Nup53 154 187  
Nup192 196 196  
Nup170Nup53Nup192 259 383 conc. dependent 
Fig. 2D 
fig. S10D 
Nup192Nup53 215 236  
Nic96 SOL 70 81  
Nup192Nup53Nic96 SOL 252 317 conc. dependent 
fig. S10E Nup170Nup53Nup192 255 383  
Nic96 SOL 70 81  
Nup170Nup53Nup192Nic96 SOL 286 464 conc. dependent 
Fig. 2E 
fig. S11A 
Nup170Nup145N 178 189  
Nup188  184 204  
Nup170Nup145N + Nup188Nup145N 227 393 partial exchange 
Fig. 2E 
fig. S11B 
Nup170Nup145N 178 189  
Nup192  178 196  
Nup170Nup145NNup192 305 385 conc. dependent 
Fig. 2E 
fig. S11C 
Nup188Nup145N 203 246  
Nup170  137 147  
Nup188Nup145N + Nup170Nup145N 193 393 partial exchange 
Fig. 2E 
fig. S11D 
Nup192Nup145N 227 238  
Nup170  137 147  
Nup192Nup145NNup170 276 385 conc. dependent 
Fig. 2E 
fig. S11E 
Nup192Nup145N 233 238  
Nup188  190 204  
Nup192Nup145N + Nup188Nup145N 223 442 partial exchange 
Fig. 2E 
fig. S11F 
Nup188Nup145N 215 246  
Nup192 180 196  
Nup188Nup145N + Nup192Nup145N 224 442 partial exchange 
Fig. 2E 
fig. S11G 
Avi-Nup192 178 194  
Nup188 178 204  
Nup145N 52 42  
Avi-Nup192Nup145N + Nup188Nup145N 223 440 partial exchange 
fig. S12A Nup170Nup145N 178 189  
Nup53 38 40  
Nup170Nup145NNup53 *inconclusive  229 stoichiometric 
fig. S12B Nup192 179 196  
Nup53 38 40  
Nup145N 40 42  
Nup192Nup53Nup145N 280 278 stoichiometric 
fig. S12C Nup170Nup53Nup145N 183 229  
Nup192 176 196  
Nup170Nup53Nup145NNup192 416 425 stoichiometric 
Fig. 2F 
fig. S13A 
Nup192  183 196  
SUMO-Nup53 31-67 16 14  
Nup192SUMO-Nup53 31-67 197 210 stoichiometric 
Fig. 2F 
fig. S14A 
Nic96 SOL 70 81  
SUMO-Nup53 1-90 21 21  
Nic96 SOLSUMO-Nup53 1-90 88 102 stoichiometric 
Fig. 2F 
fig. S14B 
Nic96 SOL 81 81  
SUMO-Nup53 69-90 16 14  
Nic96 SOLSUMO-Nup53 69-90 88 95 stoichiometric 
Fig. 2F 
fig. S14C 
Nup192  176 196  
Nic96 SOLSUMO-Nup53 1-90 81 102  
Nup192Nic96 SOLSUMO-Nup53 1-90 220 298 conc. dependent 
Fig. 2F 
fig. S17A 
Nup192 178 196  
SUMO-Nup145N 606-683 20 19  
Nup192SUMO-Nup145N 606-683 189 215 stoichiometric 
Fig. 2F 
fig. S17B 
Nup192 176 196  
Nup145N PreS 28 / 14 27 / 15  
Nup192Nup145N MID + Nup145N APD  223 223 stoichiometric 
Fig. 2F 
fig. S17C 
Nup192 NTD 100 109  
Nup145N 53 42  
Nup192 NTDNup145N 151 151 stoichiometric 
Fig. 2F 
fig. S17D 
Nup192 CTD 127 91  
Nup145N 40 42  
Nup192 CTD + Nup145N 137 133 stoichiometric 
Fig. 2F 
fig. S17E 
Nup192 TAIL  38 41  
Nup145N 46 42  
Nup192 TAIL + Nup145N 45 / 40 83 stoichiometric 
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fig. S18A Nup170 125 147  
SUMO-Nup53 31-67 16 14  
Nup170 + SUMO-Nup53 31-67 129 161 no interaction 
fig. S18B Nup170 125 147  
SUMO-Nup53 69-90 14 14  
Nup170 + SUMO-Nup53 69-90 129 161 no interaction 
fig. S18C Nup170 125 147  
SUMO-Nup145N 606-683 15 19  
Nup170+ SUMO-Nup145N 606-683 133 166 no interaction 
fig. S18D Nup192 176 196  
SUMO-Nup53 69-90 14 14  
Nup192 + SUMO-Nup53 69-90 174 210 no interaction 
fig. S18E Nup192 176 196  
GST-Nup53 329-361 55 61  
Nup192 + GST-Nup53 329-361 172 257 no interaction 
fig. S18F Nup192 176 196  
GST-Nup145N 729-750 55 59  
Nup192 + GST-Nup145N 729-750 172 255 no interaction 
fig. S18G Nic96 SOL 70 81  
SUMO-Nup53 31-67 16 14  
Nic96 + SUMO-Nup53 31-67 74 95 no interaction 
fig. S18H Nic96 SOL 70 81  
GST-Nup53 329-361 55 61  
Nic96 + GST-Nup53 329-361 66 142 no interaction 
Fig. 2F 
fig. S19B 
Nup188  181 204  
Nup145N PreS 28 / 14 27 / 15  
Nup188Nup145N MID + Nup145N APD 213 231 stoichiometric 
Fig. 2F 
fig. S19C 
Nup188 178 204  
SUMO-Nup145N 606-750 37 27  
Nup188SUMO-Nup145N 606-750 202 231 stoichiometric 
Fig. 2F 
fig. S19D 
Nup188 179 204  
SUMO-Nup145N 606-683 21 19  
Nup188 + SUMO-Nup145N 606-683 173 223 no interaction 
Fig. 2F 
fig. S19E 
Nup188 178 204  
GST-Nup145N 729-750 55 59  
Nup188 + GST-Nup145N 729-750 188 263 weak interaction 
fig. S39A Nic96 SOL 72 81  
Nup53 RRM 13 13  
Nic96 SOL + Nup53 RRM  73 94 no interaction 
fig. S39B Nup170  133 147  
Nup53 RRM 12 13  
Nup170 + Nup53 RRM  132 160 no interaction 
fig. S39C Nup192  183 196  
Nup53 RRM 14 13  
Nup192 + Nup53 RRM  182 209 no interaction 
fig. S39D Nup188 183 204  
Nup53 RRM 14 13  
Nup188 + Nup53 RRM  182 209 no interaction 
fig. S44B Nup120Nup37ELYS 209 239  
Nup84Nup133 241 258  
Nup120Nup37ELYSNup84Nup133 264 497 weak interaction 
fig. S44C Nup120Nup37ELYS 209 239  
Nup84Nup133 ΔNTE 233 246  




Crystallization and cryoprotection conditions 
Protein(s) Concentration Crystallization condition Cryo protection condition 
Nup170NTD•Nup53R3 20 mg/ml Nup170NTD 
3-fold molar excess Nup53R3 
1.0 M Na/K phosphate (pH 6.9) 
 
Mother liquor gradually supplemented to 
25 % (v/v) ethylene glycol in 5 % steps 
Nup170CTD•Nup145NR3 20 mg/ml Nup170CTD 
3-fold molar excess Nup145NR3 
12 % (w/v) PEG 3,350 
0.2 M lithium acetate 
Mother liquor gradually supplemented to 
25 % (v/v) ethylene glycol in 5 % steps 
Nup170CTD SeMet 15 mg/ml 0.1 M MES (pH 6.3) 
10 % PEG 20,000 
10 % (v/v) ethylene glycol 
0.2 M potassium thiocyanate 
Mother liquor gradually supplemented to 
25 % (v/v) ethylene glycol in 5 % steps 
Nup170CTD 30 mg/ml 0.1 M HEPES (pH 7.0) 
1.0 M sodium acetate 
Mother liquor gradually supplemented to 
25 % (v/v) ethylene glycol in 5 % steps 
Nup170SOL 7 mg/ml 0.1 M HEPES (pH 7.1) 
0.5 M ammonium sulfate 
Mother liquor gradually supplemented to 
25 % (v/v) ethylene glycol in 5 % steps 
Nic96SOL•Nup53R2 12 mg/ml 0.1 M TRIS (pH 7.0) 
12 % (w/v) PEG 6,000 
1.2 M sodium chloride 
Paratone N 
Nic96SOL 12 mg/ml 4 % Tacsimate (pH 7.4) 
14 % (w/v) PEG 3,350 
Paratone N 
Nup192∆HEAD 7 mg/ml 0.1 M TRIS (pH 7.9) 
6 % (w/v) PEG 4,000 
5 % (v/v) polypropylene glycol 
Stabilized in 
0.1 M TRIS (pH 7.9) 
7 % (w/v) PEG 4,000 
6 % (v/v) polypropylene glycol 
Solution gradually supplemented to 
25 % (v/v) polypropylene glycol 
in 5 % steps 
Nup53RRM 15 mg/ml 0.1 M HEPES (pH 7.0) 
24 % (w/v) PEG 3,350 
0.2 M potassium iodide 
Mother liquor supplemented to 
25 % ethylene glycol 
Nup53RRM 15 mg/ml 4 % Tacsimate (pH 4.1) 
15 % (w/v) PEG 3,350 
32 % Tacsimate (pH 4.1) 
19 % (w/v) PEG 3,350 
Nup145NAPD 10 mg/ml 0.1 M citric acid (pH 3.0) 
25 % (w/v) PEG 3,350 
Mother liquor supplemented to 
25 % ethylene glycol 
Nup145NAPD•Nup145CN 10 mg/ml 0.1 M TRIS (pH 8.8) 
32 % (w/v) PEG 4,000 
0.2 M lithium sulfate 
Mother liquor supplemented to 




X-ray crystallography analysis of Nup170NTD•Nup53R3 and Nup170SOL 
      
Data collection      
Protein Nup170NTD•Nup53R3 Nup170NTD•Nup53R3 Nup170SOL 
 
Nup170SOL g Nup170SOL g 
PDB ID  5HAX  5HB1  
Synchrotron APSa APS SSRLb SSRL SSRL 
Beamline 23-ID-D 23-ID-D BL12-2 BL12-2 BL12-2 
Space group P212121 P212121 P21212 P21212 P21212 
Cell dimensions      
    a, b, c (Å) 68.7, 104.0, 119.0 69.2, 106.2, 120.1 93.2, 136.9, 89.0 96.0, 138.5, 89.2 96.0, 138.5, 89.2 
    α, β, γ (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
 Se Peak  Se Peak   
Wavelength 0.9792 1.0332 0.9791 1.0330  
Resolution (Å) 50.0 – 2.5 50.0 – 2.1 50.0 – 4.5 40.0 – 4.0  40.0 – 4.3 
Rmeas (%)c 8.5 (127.7) 8.0 (188.5) 13.1 (290.0) 5.7 (353.7) 5.1 (121.5) 
Rpim (%)c 1.7 (24.9) 2.2 (51.1) 3.7 (85.0) 1.7 (98.5) 1.5 (33.0) 
CC1/2c 100.0 (86.6) 100.0 (68.1) 99.9 (56.0) 100.0 (55.5) 100.0 (92.2) 
< I / σI >c 30.4 (2.4) 20.3 (1.8) 11.6 (1.0) 18.5 (0.8) 22.8 (2.5) 
Completeness (%)c 98.9 (90.7) 100.0 (100.0) 99.3 (94.1) 99.7 (98.5) 99.8 (99.9) 
No. of observations 776,896 676,933 91,230 135,558 108,324 
No. of unique reflectionsc,d 30,229 (2,703) 52,358 (5,120) 7,200 (649) 10,614 (1,027) 8,524 (845) 
Redundancyc 25.7 (25.2) 12.9 (13.5) 12.7 (11.1) 12.8 (12.4) 12.7 (13.4) 
      
Refinement      
Resolution (Å)  50.0 – 2.1  40.0 – 4.0  
No. of reflections  52,342  7,867e  
No. of reflections test set  2,618 (5.0%)  789 (10.0%)  
Rwork / Rfree  19.9 / 23.0  30.4 / 35.2  
No. atoms  5,998  5,895  
    Protein  5,581  5,895  
    Water  387  0  
    Ligand/Ions  30  0  
B-factors  62  222  
    Protein  63  222  
    Water  57  -  
    Ligand/Ions  79  -  
RMSD      
    Bond lengths (Å)   0.002  0.003  
    Bond angles (°)  0.5  0.5  
      
Ramachandran plotf      
    Favored (%)  97.6  96.8  
    Additionally allowed (%)  2.4  3.2  
    Outliers (%)  0.0  0.0  
      
MolProbity      
    Clashscoref  0.18 (100th percentile)  1.95 (100th percentile)  
    Molprobity scoref  0.79 (100th percentile)  1.46 (100th percentile)  
      
aAPS, Advanced Photon Source 
bSSRL, Stanford Synchotron Radiation Lightsource 
cHighest-resolution shell is shown in parentheses 
dFriedel pairs were merged 
eRefinement was performed with ellipsoidally truncated data 
fAs determined by MolProbity 
gAs a reference, two different high-resolution cutoffs are shown 
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Table S6. 
X-ray crystallography analysis of apo Nup170CTD and Nup170CTD•Nup145NR3 
    




PDB ID 5HAY 5HAZ 5HB0 
Synchrotron SSRLa APSb APS 
Beamline BL12-2 23-ID-D 23-ID-D 
Space group P212121 P212121 P1 
Cell dimensions    
    a, b, c (Å) 61.8, 101.7, 193.8 69.2, 106.2, 120.1 74.6, 111.47, 111.75 
    α, β, γ (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 91.8, 92.5, 91.4 
 Se Peak   
Wavelength 0.9795 1.0332 1.0332 
Resolution (Å) 50.0 – 2.8 50.0 – 2.1 50.0 – 3.5 
Rmeas (%)c 11.6 (99.9) 5.4 (89.5) 41.4 (179.9) 
Rpim (%)c 2.8 (25.2) 2.1 (33.8) 15.6 (67.6) 
CC1/2c 99.9 (81.8) 99.9 (85.0) 98.4 (51.7) 
< I / σI >c 22.4 (2.9) 21.0 (2.0) 6.2 (1.3) 
Completeness (%)c 98.2 (82.2) 97.8 (93.9) 98.8 (94.9) 
No. of observations 500,568 325,202 317,882 
No. of unique reflectionsc 30,966 (2,527) 47,908 (4,589) 45,493 (4,380) 
Redundancyc 16.2 (14.2) 6.8 (6.8) 7.0 (6.9) 
    
Refinement    
Resolution (Å) 50.0 – 2.8 50.0 – 2.1 50.0 – 3.5 
No. of reflections 30,817 47,882 45,466 
No. of reflections test set 1,544 (5.0%) 2,395 (5.0%) 2,011 (4.4%) 
Rwork / Rfree 20.9 / 25.1 20.6 / 23.1 21.0 / 26.0 
No. atoms (non-hydrogen) 8,613 4,919 16,998 
    Protein 8,564 4,517 16,998 
    Water 48 378 0 
    Ligand/Ions 1 24 0 
B-factors 65 69 89 
    Protein 65 69 89 
    Water 57 64 - 
    Ligand/Ions 62 117 - 
RMSD    
    Bond lengths (Å)  0.003 0.004 0.005 
    Bond angles (°) 0.6 0.6 0.6 
    
Ramachandran plote    
    Favored (%) 97.2 97.5 95.1 
    Additionally allowed (%) 2.8 2.5 4.9 
    Outliers (%) 0.0 0.0 0.0 
    
MolProbity    
    Clashscoree 1.35 (100th percentile) 1.44 (100th percentile) 1.98 (100th percentile) 
    Molprobity scoree 1.29 (100th percentile) 1.27 (100th percentile) 1.55 (100th percentile) 
    
aSSRL, Stanford Synchotron Radiation Lightsource 
bAPS, Advanced Photon Source 
cHighest-resolution shell is shown in parentheses 
dFriedel pairs were merged 
eAs determined by MolProbity 
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Table S7. 
X-ray crystallography analysis of apo Nic96SOL, Nup96SOL•Nup53R2 and Nup192∆HEAD 
     
Data collection     
Protein Nic96SOL Nup96SOL•Nup53R2 Nup192∆HEAD f Nup192∆HEAD f 
PDB ID 5HB2 5HB3 5HB4  
Synchrotron APSa SSRLb SSRL SSRL 
Beamline 23-ID-B BL12-2 BL12-2 BL12-2 
Space group P21 P1 C2 C2 
Cell dimensions     
    a, b, c (Å) 53.0, 72.9, 122.7 59.5, 87.0, 98.1 190.7, 53.5, 171.8 190.7, 53.5, 171.8 
    α, β, γ (°) 90.0, 93.6, 90.0 100.7, 99.6, 95.7 90.0, 108,3, 90.0 90.0, 108,3, 90.0 
 Se Peak  Os Peak Os Peak 
Wavelength 0.9792 1.0000 1.1250 1.1250 
Resolution (Å) 50.0 – 3.3  50.0 – 2.65 50.0 – 3.2 50.0 – 3.5 
Rmeas (%)c 13.7 (104.2) 7.7 (83.7) 20.8 (325.0) 16.5 (151.7) 
Rpim (%)c 5.0 (38.7) 3.9 (49.4) 5.7 (92.5) 4.5 (40.9) 
CC1/2c 99.8 (85.1) 99.9 (81.5) 99.9 (37.5) 99.9 (74.7) 
< I / σI >c 12.0 (2.5) 15.1 (2.1) 12.1 (0.8) 15.5 (2.1) 
Completeness (%)c 100.0 (99.8) 88.6 (82.4) 98.6 (92.0) 99.4 (99.1) 
No. of observations 107,569 189,415 367,182 280,883 
No. of unique reflectionsc,d 14,334 (1,400) 48,566 (4,513) 27,800 (2,557) 21,186 (2,077) 
Redundancyc 7.5 (7.0) 3.9 (3.8) 13.2 (11.8) 13.3 (13.7) 
     
Refinement     
Resolution (Å) 50.0 – 3.3 50.0 – 2.65 50.0 – 3.2  
No. of reflections 14,284 48,536 27,512  
No. of reflections test set 1,410 (9.9%) 2,368 (4.9%) 1,377 (5.0%)  
Rwork / Rfree 23.1 / 27.8 21.1 / 24.9 23.3 / 26.5  
No. atoms (non-hydrogen) 5,674 11,569 11,035  
    Protein 5,674 11,495 11,030  
    Water - 71 0  
    Ligand/Ions - 3 5  
B-factors 127 64 136  
    Protein 127 65 136  
    Water - 45 -  
    Ligand/Ions - 57 167  
RMSD     
    Bond lengths (Å)  0.003 0.004 0.002  
    Bond angles (°) 0.6 0.9 0.5  
     
Ramachandran plote     
    Favored (%) 94.2 96.0 95.2  
    Additionally allowed (%) 5.8 4.0 4.8  
    Outliers (%) 0.0 0.0 0.0  
     
MolProbity     
    Clashscoree 3.10 (100th percentile) 3.71 (99th percentile) 1.27 (100th percentile)  
    Molprobity scoree 1.84 (100th percentile) 1.43 (100th percentile) 1.24 (100th percentile)  
     
aAPS, Advanced Photon Source 
bSSRL, Stanford Synchotron Radiation Lightsource 
cHighest-resolution shell is shown in parentheses 
dFriedel pairs were merged 
eAs determined by MolProbity  
fAs a reference, two different high-resolution cutoffs are shown 
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Table S8. 
X-ray crystallography analysis of Nup145NAPD and Nup145NAPD•Nup145CN 
   
Data collection   
Protein Nup145NAPD Nup145NAPD•Nup145CN 
PDB ID 5HB5 5HB6 
Synchrotron SSRLa ALSb 
Beamline BL12-2 8.2.2 
Space group P21 P1 
Cell dimensions   
    a, b, c (Å) 46.1, 34.9, 78.2 43.0, 44.1, 45.3 
    α, β, γ (°) 90.0, 99.4, 90.0 99.8, 111.0, 105.9 
   
Wavelength 0.9795 1.0000 
Resolution (Å) 30.0 – 1.5 30.0 – 1.3 
Rmeas (%)c 9.4 (100.4) 5.9 (110.5) 
Rpim (%)c 3.6 (39.1) 2.2 (56.0) 
CC1/2c 99.9 (87.6) 99.9 (61.7) 
< I / σI >c 12.4 (2.3) 17.2 (1.4) 
Completeness (%)c 97.2 (92.8) 94.7 (88.9) 
No. of observations 257,064 461,854 
No. of unique reflectionsc.d 38,743 (3,651) 66,722 (6,234) 
Redundancyc 6.6 (6.3) 6.9 (3.8) 
   
Refinement   
Resolution (Å) 30.0 – 1.5 30.0 – 1.3 
No. of reflections 38,683 66,707 
No. of reflections test set 2,012 (5.2%) 1,792 (2.7%) 
Rwork / Rfree 16.1 / 18.9 15.1 / 17.4 
No. atoms (non-hydrogen) 2,753 2,848 
    Protein 2,331 2,351 
    Water 331 472 
    Ligand/Ions 91 25 
B-factors 21 25 
    Protein 18 23 
    Water 32 36 
    Ligand/Ions 61 37 
RMSD   
    Bond lengths (Å)  0.005 0.008 
    Bond angles (°) 0.8 1.0 
   
Ramachandran plote   
    Favored (%) 95.9 94.6 
    Additionally allowed (%) 4.1 5.1 
    Outliers (%) 0.0 0.3 
   
MolProbity   
    Clashscoree 0.42 (100th percentile) 1.47 (99th percentile) 
    Molprobity scoree 0.99 (99th percentile) 1.31 (91st percentile) 
   
aSSRL, Stanford Synchotron Radiation Lightsource 
bALS, Advanced Light Source 
cHighest-resolution shell is shown in parentheses 
dFriedel pairs were merged 
eAs determined by MolProbity 
157
Table S9. 
X-ray crystallographic analysis of Nup53RRM 
      
Data collection      
Protein Nup53RRM e Nup53RRM e Nup53RRM Nup53RRM Nup53RRM 
PDB ID 5HB7   5HB8  
Synchrotron SSRLa SSRLa SSRL SSRL SSRL 
Beamline BL12-2 BL12-2 BL12-2 BL12-2 BL12-2 
Space group P212121 P212121 P212121 P3121 P3121 
Cell dimensions      
    a, b, c (Å) 35.0, 50.4, 60.0 35.0, 50.4, 60.0 34.9, 50.4, 60.0 94.7, 94.7, 115.5 93.8, 97.8, 114.1 
    α, β, γ (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 120.0 90.0, 90.0, 120.0 
   Se Peak  Os Peak 
Wavelength 0.7293 0.7293 0.9794 0.9794 1.1399 
Resolution (Å) 40.0 – 0.80 40.0 – 1.0 40.0 – 1.1  50.0 – 1.7 20.0 – 3.1 
Rmeas (%)b 4.1 (94.5) 3.8 (12.1) 10.4 (111.0) 7.9 (155.6) 13.5 (154.4) 
Rpim (%)b 1.3 (33.2) 1.2 (3.7) 2.1 (28.1) 1.3 (29.6) 3.7 (41.8) 
CC1/2b 99.9 (66.4) 99.9 (99.6) 99.9 (66.6) 100.0 (74.5) 99.8 (76.1) 
< I / σI >b 29.3 (2.3) 43.5 (18.8) 19.8 (2.1) 37.3 (2.2) 20.2 (1.8) 
Completeness (%)b 88.4 (50.3) 97.1 (94.8) 95.4 (66.8) 91.1 (93.1) 99.9 (99.3) 
No. of observations 890,036 550,262 984,014 2,169,719 147,214 
No. of unique reflectionsb,c 92,712 (5,211) 56,349 (5,425) 42,372 (2,914) 60,735 (6,155) 10,957 (1,073) 
Redundancyb 9.6 (7.6) 9.8 (10.3) 23.2 (14.6) 35.7 (25.9) 13.4 (13.2) 
      
Refinement      
Resolution (Å) 40.0 – 0.8   50.0 – 1.7  
No. of reflections 92,709   59,806  
No. of reflections test set 4,650 (5.0%)   1,812 (3.0%)  
Rwork / Rfree 11.8 / 13.2   16.3 / 21.0  
No. atoms (non-hydrogen) 1,448   4,176  
    Protein 1,192   3,632  
    Water 253   466  
    Ligand/Ions 3   78  
B-factors 15   38  
    Protein 11   37  
    Water 31   43  
    Ligand/Ions 16   73  
RMSD      
    Bond lengths (Å)  0.008   0.010  
    Bond angles (°) 1.1   1.0  
      
Ramachandran plotd      
    Favored (%) 98.6   99.3  
    Additionally allowed (%) 1.4   0.7  
    Outliers (%) 0.0   0.0  
      
MolProbity      
    Clashscored 0.43 (95th percentile)   0.96 (99th percentile)  
    Molprobity scored 0.65 (98th percentile)   0.88 (100th percentile)  
      
aSSRL, Stanford Synchotron Radiation Lightsource 
bHighest-resolution shell is shown in parentheses 
cFriedel pairs were merged 
dAs determined by MolProbity 





















Symmetric Core (observed in composite structure)  Symmetric Core (observed in composite structure) 
Nup120 32 141.8 4537.6  Nup160 32 162.1 5187.2 
Nup37 32 80.3 2569.6  Nup37 32 36.7 1174.4 
- - - -  Nup43 32 42.2 1350.4 
Nup85 32 128.1 4099.2  Nup85 32 75.0 2400.0 
- - - -  Seh1 32 39.7 1270.4 
Sec13 32 33.8 1081.6  Sec13 32 35.5 1136.0 
Nup145C 32 88.8 2841.6  Nup96 32 105.9 3388.8 
Nup84 32 108.1 3459.2  Nup107 32 106.4 3404.8 
Nup133 32 150.7 4822.4  Nup133 32 129.0 4128.0 
Nup170 48 156.2 7497.6  Nup155 48 155.2 7449.6 
Nup192 32 196.9 6300.8  Nup205 32 227.9 7292.8 
Nic96 32 121.5 3888.0  Nup93 32 93.5 2992.0 
Nup57 32 36.9 1180.8  Nup54 32 55.4 1772.8 
Nup49 32 48.6 1555.2  Nup58 32 53.2 1702.4 
Nsp1 32 67.1 2147.2  Nup62 32 53.3 1705.6 
Nup53 48 47.0 2256.0  Nup53 48 34.8 1670.4 
Nup145N 48 99.8 4790.4  Nup98 48 91.7 4401.6 
Nup188 16 203.8 3260.8  Nup188 16 196.0 3136.0 
TOTAL   56288.0  TOTAL   55563.2 
  
 
 Cytoplasmic Filaments  Cytoplasmic Filaments	 	
- - -   Nup358 - 358.2  
Nup159 - 156.2 
 
 Nup214 - 213.6 
 Nup82 - 98.1  Nup88 - 83.5 
 Gle1 - 58.0   Gle1 - 79.8 
Gle2 - 39.4 
 
 Rae1 - 41.0  
Nup42 - 58.0 
 
 Nupl2 - 44.9  
    
 
   Nuclear Basket  Nuclear Basket 
Mlp1 - 231.1 
 
 TPR - 267.3  
Nup152 - 152.2 
 
 Nup153 - 153.9 
 Nup56 - 56.2 
 
 Nup50 - 50.1 
ELYS - 33.1  ELYS - 252.5  
    
     
 POMs/Other  POMs/Other 
Pom152 - 141.5   Gp210 - 205.1  
- - -   POM121 - 127.7 
 Ndc1 - 71.8   NDC1 - 76.3 
Pom34 - 34.2       
- - -   ALADIN - 59.6  
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